Disease on EC 1.1.1.146 - 11beta-hydroxysteroid dehydrogenase
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
11beta-hydroxysteroid dehydrogenase deficiency
11beta-hydroxysteroid dehydrogenase in cultured human vascular cells. Possible role in the development of hypertension.
11beta-hydroxysteroid dehydrogenase deficiency
11beta-hydroxysteroid dehydrogenase type 1 deficiency ('apparent cortisone reductase deficiency') in a 6-year-old boy.
11beta-hydroxysteroid dehydrogenase deficiency
11Beta-hydroxysteroid dehydrogenase-1 deficiency or inhibition enhances hepatic myofibroblast activation in murine liver fibrosis.
11beta-hydroxysteroid dehydrogenase deficiency
A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia.
11beta-hydroxysteroid dehydrogenase deficiency
Cortisol metabolism in the postoperative period after cardiac surgery.
11beta-hydroxysteroid dehydrogenase deficiency
Defects in the HSD11 gene encoding 11 beta-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency.
11beta-hydroxysteroid dehydrogenase deficiency
Endothelial cell dysfunction in mice after transgenic knockout of type 2, but not type 1, 11beta-hydroxysteroid dehydrogenase.
11beta-hydroxysteroid dehydrogenase deficiency
Enhanced hippocampal long-term potentiation and spatial learning in aged 11beta-hydroxysteroid dehydrogenase type 1 knock-out mice.
11beta-hydroxysteroid dehydrogenase deficiency
Epidemiologic study of adrenal gland disorders in Japan.
11beta-hydroxysteroid dehydrogenase deficiency
Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome.
11beta-hydroxysteroid dehydrogenase deficiency
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue.
11beta-hydroxysteroid dehydrogenase deficiency
Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice.
11beta-hydroxysteroid dehydrogenase deficiency
Interactions between 11beta-hydroxysteroid dehydrogenase and COX-2 in kidney.
11beta-hydroxysteroid dehydrogenase deficiency
Low doses of liquorice can induce hypertension encephalopathy.
11beta-hydroxysteroid dehydrogenase deficiency
Pubertal presentation of congenital delta 5-3 beta-hydroxysteroid dehydrogenase deficiency.
11beta-hydroxysteroid dehydrogenase deficiency
Regulation of the genes for 11beta-hydroxysteroid dehydrogenase type 1 and type 2 in the kidney of the Dahl rat.
11beta-hydroxysteroid dehydrogenase deficiency
Renin-Independent hypermineralocorticoidism.
11beta-hydroxysteroid dehydrogenase deficiency
The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes.
3alpha(or 20beta)-hydroxysteroid dehydrogenase deficiency
11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.
3alpha(or 20beta)-hydroxysteroid dehydrogenase deficiency
11{beta}-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response.
3alpha(or 20beta)-hydroxysteroid dehydrogenase deficiency
A study of the hexose-6-phosphate dehydrogenase gene R453Q and 11beta-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome.
3alpha(or 20beta)-hydroxysteroid dehydrogenase deficiency
Alterations of Cortisol Metabolism in Human Disorders.
3alpha(or 20beta)-hydroxysteroid dehydrogenase deficiency
Apparent cortisone reductase deficiency: a functional defect in 11beta-hydroxysteroid dehydrogenase type 1.
3alpha(or 20beta)-hydroxysteroid dehydrogenase deficiency
Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase.
3alpha(or 20beta)-hydroxysteroid dehydrogenase deficiency
Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome.
3alpha(or 20beta)-hydroxysteroid dehydrogenase deficiency
Genotypes at 11beta-hydroxysteroid dehydrogenase type 11B1 and hexose-6-phosphate dehydrogenase loci are not risk factors for apparent cortisone reductase deficiency in a large population-based sample.
3alpha(or 20beta)-hydroxysteroid dehydrogenase deficiency
Lack of Association of the 11beta-hydroxysteroid dehydrogenase type 1 gene 83,557insA and hexose-6-phosphate dehydrogenase gene R453Q polymorphisms with body composition, adrenal androgen production, blood pressure, glucose metabolism, and dementia.
3alpha(or 20beta)-hydroxysteroid dehydrogenase deficiency
Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency.
3alpha(or 20beta)-hydroxysteroid dehydrogenase deficiency
Novel H6PDH mutations in two girls with premature adrenarche: 'apparent' and 'true' CRD can be differentiated by urinary steroid profiling.
3alpha(or 20beta)-hydroxysteroid dehydrogenase deficiency
Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency.
Acidosis
Effects of changes in dietary intake of sodium and potassium and of metabolic acidosis on 11beta-hydroxysteroid dehydrogenase activities in rat kidney.
Acidosis
Effects of sustained hypoxaemia with 72 hours recovery on 11beta-hydroxysteroid dehydrogenase types 1 and 2 gene expression in near-term fetal sheep.
Acromegaly
Immunohistochemical analysis of 11-beta-hydroxysteroid dehydrogenase type 2 and glucocorticoid receptor in subclinical Cushing's disease due to pituitary macroadenoma.
Acromegaly
Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly.
Acromegaly
Modulation of cortisol metabolism during treatment of acromegaly is independent of body composition and insulin sensitivity.
ACTH-Secreting Pituitary Adenoma
Effects of Carbenoxolone on the Canine Pituitary-Adrenal Axis.
ACTH-Secreting Pituitary Adenoma
Expression of genes related to corticotropin production and glucocorticoid feedback in corticotroph adenomas of dogs with Cushing's disease.
ACTH-Secreting Pituitary Adenoma
Inhibition of 11beta-hydroxysteroid dehydrogenase eliminates impaired glucocorticoid suppression and induces apoptosis in corticotroph tumor cells.
Acute Lung Injury
Inflammatory mediators down-regulate 11beta-hydroxysteroid dehydrogenase type 2 in a human lung epithelial cell line BEAS-2B and the rat lung.
Addison Disease
Polymorphic variants of the HSD11B1 gene may be involved in adverse metabolic effects of glucocorticoid replacement therapy in Addison's disease.
Addison Disease
Polymorphisms of the GR and HSD11B1genes influence body mass index and weight gain during hormone replacement treatment in patients with Addison's disease.
Adenocarcinoma
Inflammation-associated gene expression is altered between normal human ovarian surface epithelial cells and cell lines derived from ovarian adenocarcinomas.
Adenocarcinoma
Regulation of 11beta-hydroxysteroid dehydrogenase type 2 by steroid hormones and epidermal growth factor in the Ishikawa human endometrial cell line.
Adenoma
11beta-Hydroxysteroid dehydrogenase types 1 and 2 are up- and downregulated in cortisol-secreting adrenal adenomas.
Adenoma
A case of cortisol producing adrenal adenoma without phenotype of Cushing's syndrome due to impaired 11beta-hydroxysteroid dehydrogenase 1 activity.
Adenoma
Cortisol-secreting adrenal adenomas express 11beta-hydroxysteroid dehydrogenase type-2 gene yet possess low 11beta-HSD2 activity.
Adenoma
Expression of 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD-2) in the developing human adrenal gland and human adrenal cortical carcinoma and adenoma.
Adenoma
Human adrenal cortex and aldosterone secreting adenomas express both 11beta-hydroxysteroid dehydrogenase type 1 and type 2 genes.
Adenoma
Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.
Adenoma
Role of local 11 beta-hydroxysteroid dehydrogenase type 2 expression in determining the phenotype of adrenal adenomas.
Adenoma
Role of local 11beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) expression in determining the phenotype of adrenal adenomas.
Adrenal Hyperplasia, Congenital
11Beta-Hydroxylase Deficiency and Other Syndromes of Mineralocorticoid Excess as a Rare Cause of Endocrine Hypertension.
Adrenal Hyperplasia, Congenital
Effect of carbenoxolone on the plasma renin activity and hypothalamic-pituitary-adrenal axis in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Adrenal Hyperplasia, Congenital
Failure of cortisone acetate treatment in congenital adrenal hyperplasia because of defective 11beta-hydroxysteroid dehydrogenase reductase activity.
Adrenal Insufficiency
Effect of growth hormone deficiency and recombinant hGH (rhGH) replacement on the hypothalamic-pituitary-adrenal axis in children with idiopathic isolated GH deficiency.
Adrenal Insufficiency
Mechanism of adrenal insufficiency following trauma and severe hemorrhage: role of hepatic 11beta-hydroxysteroid dehydrogenase.
Adrenal Insufficiency
Placental 11beta-HSD2 activity, early postnatal clinical course, and adrenal function in extremely low birth weight infants.
Adrenal Insufficiency
The role of progesterone metabolism and androgen synthesis in renal blood pressure regulation.
Adrenocortical Adenoma
Cortisol-secreting adrenal adenomas express 11beta-hydroxysteroid dehydrogenase type-2 gene yet possess low 11beta-HSD2 activity.
Adrenocortical Carcinoma
Expression of 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD-2) in the developing human adrenal gland and human adrenal cortical carcinoma and adenoma.
Adrenocortical Carcinoma
Uneventful delivery following series of successive treatments for virilized Cushing syndrome due to adrenocortical carcinoma.
Adrenogenital Syndrome
[Unusual adrenogenital syndrome. Probable blockade of 3 beta-hydroxysteroid dehydrogenase in a 4-year-old boy]
Albuminuria
Expression of renal 11beta-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function.
Alkalosis
Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases.
Alkalosis
Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess.
Alkalosis
Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene.
Alopecia
delta 5-3 beta-hydroxysteroid dehydrogenase activity in sebaceous glands of scalp in male-pattern baldness.
Alzheimer Disease
Quantitative measurements of corticosteroids in ex vivo samples using on-line SPE-LC/MS/MS.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Clinical outcome in anti-neutrophil cytoplasmic antibody-associated vasculitis and gene variants of 11?-hydroxysteroid dehydrogenase type 1 and the glucocorticoid receptor.
Arthritis
11 Beta-hydroxysteroid dehydrogenase type 1 regulates synovitis, joint destruction, and systemic bone loss in chronic polyarthritis.
Arthritis
Arthritis and endogenous glucocorticoids: the emerging role of the 11beta-HSD enzymes.
Arthritis, Experimental
Local metabolism of glucocorticoids and its role in rat adjuvant arthritis.
Arthritis, Rheumatoid
11 Beta-hydroxysteroid dehydrogenase type 1 regulates synovitis, joint destruction, and systemic bone loss in chronic polyarthritis.
Arthritis, Rheumatoid
Differential expression, function and response to inflammatory stimuli of 11beta-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation.
Asthma
Clinical relevance of airway 11beta-hydroxysteroid dehydrogenase type II enzyme in asthma.
Asthma
Cortisol resistance in conditions such as asthma and the involvement of 11beta-HSD-2: a hypothesis.
Asthma
Effect of inhaled glucocorticoid treatment on placental 11beta-hydroxysteroid dehydrogenase type 2 activity and neonatal birthweight in pregnancies complicated by asthma.
Asthma
Postmenopausal asthma: the estradiol 11beta-hydroxysteroid dehydrogenase connection.
Asthma
Reduced 11beta-hydroxysteroid dehydrogenase type 2 activity is associated with decreased birth weight centile in pregnancies complicated by asthma.
Atherosclerosis
11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.
Atherosclerosis
11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.
Atherosclerosis
7-oxysterols modulate glucocorticoid activity in adipocytes through competition for 11beta-hydroxysteroid dehydrogenase type.
Atherosclerosis
Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
Atherosclerosis
Human and rodent type 1 11beta-hydroxysteroid dehydrogenases are 7beta-hydroxycholesterol dehydrogenases involved in oxysterol metabolism.
Atherosclerosis
Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.
Atherosclerosis
Rapid hepatic metabolism of 7-ketocholesterol by 11beta-hydroxysteroid dehydrogenase type 1: species-specific differences between the rat, human, and hamster enzyme.
Atherosclerosis
The role of the Stress-Related Anti-Inflammatory Hormones ACTH and Cortisol in Atherosclerosis.
Atherosclerosis
Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.
Atrial Fibrillation
Increased expression of mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 2 in human atria during atrial fibrillation.
Atrial Fibrillation
[Atrial 11beta-hydroxysteroid dehydrogenase type 2 expression in rheumatic heart disease patients with or without atrial fibrillation]
Atrial Fibrillation
[Expression of mineralocorticoid receptor and 11-beta-hydroxysteroid dehydrogenase type 2 in human atria during chronic atrial fibrillation: study of 25 cases]
Brain Ischemia
11beta-hydroxysteroid dehydrogenase type II inhibition causes cerebrovascular remodeling and increases infarct size after cerebral ischemia.
Breast Neoplasms
Contribution of protein kinase A and protein kinase C signalling pathways to the regulation of HSD11B2 expression and proliferation of MCF-7 cells.
Breast Neoplasms
Expression of the 11beta-hydroxysteroid dehydrogenase type II enzyme in breast tumors and modulation of activity and cell growth in PMC42 cells.
Breast Neoplasms
Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II.
Breast Neoplasms
Impaired 11?-Hydroxysteroid Dehydrogenase Type 2 in Glucocorticoid Resistant Patients.
Breast Neoplasms
Impairment of the antiproliferative effect of glucocorticosteroids by 11beta-hydroxysteroid dehydrogenase type 2 overexpression in MCF-7 breast-cancer cells.
Breast Neoplasms
Inhibition of 11 beta-hydroxysteroid dehydrogenase activity enhances the antiproliferative effect of glucocorticosteroids on MCF-7 and ZR-75-1 breast cancer cells.
Breast Neoplasms
Progesterone induction of the 11beta-hydroxysteroid dehydrogenase type 2 promoter in breast cancer cells involves coordinated recruitment of STAT5A and progesterone receptor to a distal enhancer and polymerase tracking.
Breast Neoplasms
Progestin regulation of 11beta-hydroxysteroid dehydrogenase expression in T-47D human breast cancer cells.
Breast Neoplasms
The 11beta-hydroxysteroid dehydrogenases: functions and physiological effects.
Breast Neoplasms
The 5,6-epoxycholesterol metabolic pathway in breast cancer: Emergence of new pharmacological targets.
Breast Neoplasms
[Diseases caused by adrenal dyshormonogenesis. The concept of minor enzymopathy. The 3 beta-hydroxysteroid dehydrogenase block; its possible importance in the pathogenesis of breast cancer]
Carcinogenesis
Immunohistochemical analysis of 11-beta-hydroxysteroid dehydrogenase type 2 and glucocorticoid receptor in subclinical Cushing's disease due to pituitary macroadenoma.
Carcinogenesis
Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.
Carcinogenesis
Prereceptor regulation of glucocorticoid action by 11beta-hydroxysteroid dehydrogenase: a novel determinant of cell proliferation.
Carcinoma
11Beta-hydroxysteroid dehydrogenase 1 expression in squamous cell carcinomas of the head and neck.
Carcinoma
Expression of 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD-2) in the developing human adrenal gland and human adrenal cortical carcinoma and adenoma.
Carcinoma, Hepatocellular
11 beta-hydroxysteroid dehydrogenase type 1 expression in 2S FAZA hepatoma cells is hormonally regulated: a model system for the study of hepatic glucocorticoid metabolism.
Carcinoma, Hepatocellular
C/EBP regulates hepatic transcription of 11beta -hydroxysteroid dehydrogenase type 1. A novel mechanism for cross-talk between the C/EBP and glucocorticoid signaling pathways.
Carcinoma, Hepatocellular
Expression of 11beta-hydroxysteroid dehydrogenase type 2 in an ACTH-producing small cell lung cancer.
Carcinoma, Ovarian Epithelial
Type 2 11beta-hydroxysteroid dehydrogenase activity in human ovarian cancer.
Carcinoma, Squamous Cell
11Beta-hydroxysteroid dehydrogenase 1 expression in squamous cell carcinomas of the head and neck.
Carcinosarcoma
NAD dependent 11beta-hydroxysteroid dehydrogenase activity in human endometrium and endometrial tumors.
Cardiomegaly
11beta-Hydroxysteroid dehydrogenase in the heart of normotensive and hypertensive rats.
Cardiomegaly
Chronic intermittent hypoxia induces 11beta-hydroxysteroid dehydrogenase in rat heart.
Cardiovascular Diseases
11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization.
Cardiovascular Diseases
A gene variant of 11?-hydroxysteroid dehydrogenase type 1 is associated with obesity in children.
Cardiovascular Diseases
Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.
Cardiovascular Diseases
Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Cardiovascular Diseases
Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide.
Cardiovascular Diseases
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic sindrome.
Cardiovascular Diseases
Influence of aldosterone vs. endothelin receptor antagonism on renovascular function in liquorice-induced hypertension.
Cardiovascular Diseases
Reduced placental 11beta-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms.
Cardiovascular Diseases
Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.
Cardiovascular Diseases
Tissue-specific adaptive levels of glucocorticoid receptor alpha mRNA and their relationship with insulin resistance.
Cardiovascular Diseases
Type 1 11beta-hydroxysteroid dehydrogenase as universal drug target in metabolic diseases?
Cerebrovascular Disorders
11beta-hydroxysteroid dehydrogenase type II inhibition causes cerebrovascular remodeling and increases infarct size after cerebral ischemia.
Choriocarcinoma
Angiotensin II regulates 11beta-hydroxysteroid dehydrogenase type 2 via AT2 receptors.
Choriocarcinoma
Effect of cadmium on cortisol production and 11beta-hydroxysteroid dehydrogenase 2 expression by cultured human choriocarcinoma cells (JEG-3).
Choriocarcinoma
Effect of pro-inflammatory cytokines on expression and activity of 11beta-hydroxysteroid dehydrogenase type 2 in cultured human term placental trophoblast and human choriocarcinoma JEG-3 cells.
Choriocarcinoma
Prostaglandins and leukotriene B4 are potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 2 activity in human choriocarcinoma JEG-3 cells.
Choriocarcinoma
Regulation of cytochrome P450 cholesterol side-chain cleavage, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase type 1 and estradiol-17 beta-hydroxysteroid dehydrogenase mRNA levels by calcium in human choriocarcinoma JEG-3 cells.
Choriocarcinoma
Retinoic acid stimulates the expression of 11beta-hydroxysteroid dehydrogenase type 2 in human choriocarcinoma JEG-3 cells.
Choriocarcinoma
Structure of the VPATPD gene encoding subunit D of the human vacuolar proton ATPase.
Colitis
11beta-hydroxysteroid dehydrogenase 1 and 2 expression in colon from patients with ulcerative colitis.
Colitis
Inflammation regulates 11?-hydroxysteroid dehydrogenase type 1 differentially in specific compartments of the gut mucosal immune system.
Colitis
Intestinal inflammation modulates expression of 11beta-hydroxysteroid dehydrogenase in murine gut.
Colitis
Upregulation of 11?-hydroxysteroid dehydrogenase 1 in lymphoid organs during inflammation in the rat.
Colitis, Ulcerative
11beta-hydroxysteroid dehydrogenase 1 and 2 expression in colon from patients with ulcerative colitis.
Colorectal Neoplasms
A variant (rs932335) in the HSD11B1 gene is associated with colorectal cancer in a Chinese population.
Colorectal Neoplasms
Chinese herbal medicine promote tissue differentiation in colorectal cancer by activating HSD11B2.
Colorectal Neoplasms
Expression of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in colorectal cancer.
Colorectal Neoplasms
Type-2 11?-hydroxysteroid dehydrogenase promotes the metastasis of colorectal cancer via the Fgfbp1-AKT pathway.
Congenital Abnormalities
The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes.
Cushing Syndrome
11Beta-Hydroxylase Deficiency and Other Syndromes of Mineralocorticoid Excess as a Rare Cause of Endocrine Hypertension.
Cushing Syndrome
A case of cortisol producing adrenal adenoma without phenotype of Cushing's syndrome due to impaired 11beta-hydroxysteroid dehydrogenase 1 activity.
Cushing Syndrome
Adipose tissue 11{beta}-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome.
Cushing Syndrome
Adipose tissue expression of 11beta-hydroxysteroid dehydrogenase type 1 in Cushing's syndrome and in obesity.
Cushing Syndrome
Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases.
Cushing Syndrome
Mechanism of hypertension in Cushing's syndrome: possible role of 11beta-hydroxysteroid dehydrogenase type 2 in kidneys and vascular cells.
Cushing Syndrome
Persistent hypokalemia after successful adrenalectomy in a patient with Cushing's syndrome due to ectopic ACTH secretion: possible role of 11beta-hydroxysteroid dehydrogenase inhibition.
Cushing Syndrome
Quantitative real-time PCR for the measurement of 11beta-HSD1 and 11beta-HSD2 mRNA levels in tissues of healthy dogs.
Cushing Syndrome
Reduced 11beta-hydroxysteroid dehydrogenase type 1 activity in obese boys.
Cushing Syndrome
Role of ketoconazole treatment in urinary-free cortisol-to-cortisone and tetrahydrocortisol-to-tetrahydrocortisone ratios in nonectopic Cushing's syndrome.
Cushing Syndrome
Role of local 11 beta-hydroxysteroid dehydrogenase type 2 expression in determining the phenotype of adrenal adenomas.
Cushing Syndrome
The 83,557insA variant of the gene coding 11?-hydroxysteroid dehydrogenase type 1 enzyme associates with serum osteocalcin in patients with endogenous Cushing's syndrome.
Cushing Syndrome
The activity of 11?-hydroxysteroid dehydrogenase type 2 enzyme and cortisol secretion in patients with adrenal incidentalomas.
Cushing Syndrome
Uneventful delivery following series of successive treatments for virilized Cushing syndrome due to adrenocortical carcinoma.
Cystic Fibrosis
Mimicry and well known genetic friends: molecular diagnosis in an Iranian cohort of suspected Bartter syndrome and proposition of an algorithm for clinical differential diagnosis.
Cysts
Implication of cortisol and 11beta-hydroxysteroid dehydrogenase enzymes in the development of porcine (Sus scrofa domestica) ovarian follicles and cysts.
Dementia
11Beta-hydroxysteroid dehydrogenase-1 deficiency or inhibition enhances hepatic myofibroblast activation in murine liver fibrosis.
Dementia
Lack of Association of the 11beta-hydroxysteroid dehydrogenase type 1 gene 83,557insA and hexose-6-phosphate dehydrogenase gene R453Q polymorphisms with body composition, adrenal androgen production, blood pressure, glucose metabolism, and dementia.
Depression, Postpartum
Associations between a polymorphism in the hydroxysteroid (11-beta) dehydrogenase 1 gene, neuroticism and postpartum depression.
Depression, Postpartum
Maternal Prenatal Mental Health and Placental 11?-HSD2 Gene Expression: Initial Findings from the Mercy Pregnancy and Emotional Wellbeing Study.
Dermatitis, Contact
Inhibition of skin 11beta-hydroxysteroid dehydrogenase activity in vivo potentiates the anti-inflammatory actions of glucocorticoids.
Diabetes Mellitus
11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus.
Diabetes Mellitus
11beta-Hydroxysteroid dehydrogenase Type 1: genetic polymorphisms are associated with Type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle.
Diabetes Mellitus
Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure.
Diabetes Mellitus
Association of HSD11B1 polymorphic variants and adipose tissue gene expression with metabolic syndrome, obesity and type 2 diabetes mellitus: a systematic review.
Diabetes Mellitus
Association studies between the HSD11B2 gene (encoding human 11beta-hydroxysteroid dehydrogenase type 2), type 1 diabetes mellitus and diabetic nephropathy.
Diabetes Mellitus
Benzothiazole derivatives as novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Diabetes Mellitus
INCB-13739, an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus
Inhibition of human and rat 11beta-hydroxysteroid dehydrogenase type 1 by 18beta-glycyrrhetinic acid derivatives.
Diabetes Mellitus
Lack of relationship between 11beta-hydroxysteroid dehydrogenase setpoint and insulin sensitivity in the basal state and after 24h of insulin infusion in healthy subjects and type 2 diabetic patients.
Diabetes Mellitus
Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor.
Diabetes Mellitus
Regulatory effect of common promoter polymorphisms on the expression of the 11beta-hydroxysteroid dehydrogenase type 1 gene.
Diabetes Mellitus, Experimental
[Adrenocortical and renin-angiotensin systems in dynamics of experimental diabetes].
Diabetes Mellitus, Type 1
?-Cell-Specific Glucocorticoid Reactivation Attenuates Inflammatory ?-Cell Destruction.
Diabetes Mellitus, Type 1
Association studies between the HSD11B2 gene (encoding human 11beta-hydroxysteroid dehydrogenase type 2), type 1 diabetes mellitus and diabetic nephropathy.
Diabetes Mellitus, Type 1
Variants in HSD11B1 gene modulate susceptibility to diabetes kidney disease and to insulin resistance in type 1 diabetes.
Diabetes Mellitus, Type 2
11 beta-hydroxysteroid dehydrogenase type 1 promotes differentiation of 3T3-L1 preadipocyte.
Diabetes Mellitus, Type 2
11? Hydroxysteroid dehydrogenase - 1 activity in type 2 diabetes mellitus: a comparative study.
Diabetes Mellitus, Type 2
11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.
Diabetes Mellitus, Type 2
11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational approaches.
Diabetes Mellitus, Type 2
11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics.
Diabetes Mellitus, Type 2
11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes.
Diabetes Mellitus, Type 2
11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
Diabetes Mellitus, Type 2
11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
11beta-Hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds.
Diabetes Mellitus, Type 2
11beta-Hydroxysteroid dehydrogenase Type 1: genetic polymorphisms are associated with Type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle.
Diabetes Mellitus, Type 2
2-(S)-phenethylaminothiazolones as potent, orally efficacious inhibitors of 11beta-hydroxysteriod dehydrogenase type 1.
Diabetes Mellitus, Type 2
4-(Phenylsulfonamidomethyl)benzamides as potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1 with efficacy in diabetic ob/ob mice.
Diabetes Mellitus, Type 2
A combination of polymorphisms in HSD11B1 associates with in vivo 11{beta}-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome.
Diabetes Mellitus, Type 2
Adipose tissue 11-beta-Hydroxysteroid Dehydrogenase Type 1 and Hexose-6-Phosphate Dehydrogenase gene expressions are increased in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Alteration of 11beta-hydroxysteroid dehydrogenase type 1 in skeletal muscle in a rat model of type 2 diabetes.
Diabetes Mellitus, Type 2
Altered activity of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in skeletal muscle confers metabolic protection in subjects with type 2 diabetes.
Diabetes Mellitus, Type 2
Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1.
Diabetes Mellitus, Type 2
Association of HSD11B1 gene polymorphisms with type 2 diabetes and metabolic syndrome in South Indian population.
Diabetes Mellitus, Type 2
Association of HSD11B1 polymorphic variants and adipose tissue gene expression with metabolic syndrome, obesity and type 2 diabetes mellitus: a systematic review.
Diabetes Mellitus, Type 2
beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action.
Diabetes Mellitus, Type 2
Blockade of glucocorticoid excess at the tissue level: inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 as a therapy for type 2 diabetes.
Diabetes Mellitus, Type 2
Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans.
Diabetes Mellitus, Type 2
Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Different expression and distribution of 11beta-hydroxysteroid dehydrogenase type 1 in obese and lean animal models of type 2 diabetes.
Diabetes Mellitus, Type 2
Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes.
Diabetes Mellitus, Type 2
Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Diabetes Mellitus, Type 2
Effect of licorice on patients with HSD11B1 gene polymorphisms- a pilot study.
Diabetes Mellitus, Type 2
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
Diabetes Mellitus, Type 2
Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice.
Diabetes Mellitus, Type 2
Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
Diabetes Mellitus, Type 2
Functional effects of polymorphisms in the human gene encoding 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1): a sequence variant at the translation start of 11 beta-HSD1 alters enzyme levels.
Diabetes Mellitus, Type 2
H6PDH interacts directly with 11beta-HSD1: implications for determining the directionality of glucocorticoid catalysis.
Diabetes Mellitus, Type 2
INCB-13739, an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone.
Diabetes Mellitus, Type 2
Increased glucocorticoid receptor and 11{beta}-hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db/db mice.
Diabetes Mellitus, Type 2
Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone.
Diabetes Mellitus, Type 2
Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition.
Diabetes Mellitus, Type 2
Interaction of HSD11B1 and H6PD polymorphisms in subjects with type 2 diabetes are protective factors against obesity: a cross-sectional study.
Diabetes Mellitus, Type 2
Lack of relationship between 11beta-hydroxysteroid dehydrogenase setpoint and insulin sensitivity in the basal state and after 24h of insulin infusion in healthy subjects and type 2 diabetic patients.
Diabetes Mellitus, Type 2
Liver X receptors downregulate 11beta-hydroxysteroid dehydrogenase type 1 expression and activity.
Diabetes Mellitus, Type 2
Longer HSD11B2 CA-repeat in impaired glucose tolerance and type 2 diabetes.
Diabetes Mellitus, Type 2
Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action.
Diabetes Mellitus, Type 2
Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor.
Diabetes Mellitus, Type 2
Novel non-steroidal inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Diabetes Mellitus, Type 2
Optimization of high-resolution melting analysis for simultaneous genotyping of two 11?-hydroxysteroid dehydrogenase type 1 gene polymorphisms.
Diabetes Mellitus, Type 2
Physiological roles of 11 beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase.
Diabetes Mellitus, Type 2
Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity?
Diabetes Mellitus, Type 2
Regulatory effect of common promoter polymorphisms on the expression of the 11beta-hydroxysteroid dehydrogenase type 1 gene.
Diabetes Mellitus, Type 2
Relationship of 11?-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase gene polymorphisms with metabolic syndrome and type 2 diabetes.
Diabetes Mellitus, Type 2
Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains.
Diabetes Mellitus, Type 2
Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor.
Diabetes Mellitus, Type 2
Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.
Diabetes Mellitus, Type 2
Synthesis and biological evaluation of sulfonamidooxazoles and beta-keto sulfones: selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
Diabetes Mellitus, Type 2
Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes.
Diabetes Mellitus, Type 2
The 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients with Type 2 Diabetes Inadequately Controlled By Metformin Monotherapy.
Diabetes Mellitus, Type 2
The activity of 11?-hydroxysteroid dehydrogenase type 2 enzyme and cortisol secretion in patients with adrenal incidentalomas.
Diabetes Mellitus, Type 2
The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans.
Diabetes Mellitus, Type 2
The glucocorticoid-activating enzyme 11beta-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological considerations.
Diabetes Mellitus, Type 2
The Role of 11Beta-Hydroxysteroid Dehydrogenase in Metabolic Disease and Therapeutic Potential of 11Beta-HSD1 Inhibitors.
Diabetes Mellitus, Type 2
Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
Diabetes Mellitus, Type 2
[Reduction of obesity-related metabolic risk by modulating tissue exposition to cortisol].
Diabetes, Gestational
Dysregulation of 11beta-hydroxysteroid dehydrogenases: implications during pregnancy and beyond.
Diabetic Nephropathies
Association studies between the HSD11B2 gene (encoding human 11beta-hydroxysteroid dehydrogenase type 2), type 1 diabetes mellitus and diabetic nephropathy.
Dyslipidemias
11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus.
Dyslipidemias
11beta-Hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
Dyslipidemias
Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.
Dyslipidemias
Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Dyslipidemias
Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Dyslipidemias
Overexpression of 11beta-Hydroxysteroid Dehydrogenase Type 1 in Hepatic and Visceral Adipose Tissue is Associated with Metabolic Disorders in Morbidly Obese Patients.
Dyslipidemias
Reduced levels of circulating 7alpha-hydroxy-dehydroepiandrosterone in treated adolescent obese patients.
Dyslipidemias
Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Dyslipidemias
Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.
Endometrial Neoplasms
NAD dependent 11beta-hydroxysteroid dehydrogenase activity in human endometrium and endometrial tumors.
Essential Hypertension
11beta-Hydroxysteroid dehydrogenase type 2 activity is associated with left ventricular mass in essential hypertension.
Essential Hypertension
A new polymorphic restriction site in the human 11 beta-hydroxysteroid dehydrogenase type 2 gene.
Essential Hypertension
Analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene (HSD11B2) in human essential hypertension.
Essential Hypertension
Association between ins4436A in 11?-hydroxysteroid dehydrogenase type 1 gene and essential hypertension in Polish population.
Essential Hypertension
Detection of Urinary Exosomal HSD11B2 mRNA Expression: A Useful Novel Tool for the Diagnostic Approach of Dysfunctional 11?-HSD2-Related Hypertension.
Essential Hypertension
Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide.
Essential Hypertension
Genetic variations of HSD11B2 in hypertensive patients and in the general population, six rare missense/frameshift mutations.
Essential Hypertension
Genotype-phenotype correlations of mutations and polymorphisms in HSD11B2, the gene encoding the kidney isozyme of 11beta-hydroxysteroid dehydrogenase.
Essential Hypertension
Identification of polymorphisms in the human 11beta-hydroxysteroid dehydrogenase type 2 gene promoter: functional characterization and relevance for salt sensitivity.
Essential Hypertension
Insulin, CCAAT/enhancer-binding proteins and lactate regulate the human 11?-hydroxysteroid dehydrogenase type 2 gene expression in colon cancer cell lines.
Essential Hypertension
Possible association but no linkage of the HSD11B2 gene encoding the kidney isozyme of 11beta-hydroxysteroid dehydrogenase to hypertension in Black people.
Essential Hypertension
Role of HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides.
Essential Hypertension
Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation.
Essential Hypertension
Structural analysis and evaluation of the 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) gene in human essential hypertension.
Essential Hypertension
The role of 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension.
Fatty Liver
Additive action of 11beta-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats.
Fatty Liver
Hepatic 11beta-HSD1 mRNA expression in fatty liver and non-alcoholic steatohepatitis.
Fatty Liver
Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Fetal Growth Retardation
11Beta-hydroxysteroid dehydrogenase type 2 in human pregnancy and reduced expression in intrauterine growth restriction.
Fetal Growth Retardation
Changes in 11beta-hydroxysteroid dehydrogenase type 2 expression in a low-protein rat model of intrauterine growth restriction.
Fetal Growth Retardation
Diethylstilbestrol inhibits human and rat 11?-hydroxysteroid dehydrogenase 2.
Fetal Growth Retardation
Differences in expression and activity of 11beta-hydroxysteroid dehydrogenase type 1 and 2 in human placentas of term pregnancies according to birth weight and gender.
Fetal Growth Retardation
Differential expression and activity of 11beta-hydroxysteroid dehydrogenase in human placenta and fetal membranes from pregnancies with intrauterine growth restriction.
Fetal Growth Retardation
Dysregulation of 11beta-hydroxysteroid dehydrogenases: implications during pregnancy and beyond.
Fetal Growth Retardation
Glucocorticoids, 11beta-hydroxysteroid dehydrogenase, and fetal programming.
Fetal Growth Retardation
Hypoxia blocks 11beta-hydroxysteroid dehydrogenase type 2 induction in human trophoblast cells during differentiation by a time-dependent mechanism that involves both translation and transcription.
Fetal Growth Retardation
Impact of restriction of placental and fetal growth on expression of 11beta-hydroxysteroid dehydrogenase type 1 and type 2 messenger ribonucleic acid in the liver, kidney, and adrenal of the sheep fetus.
Fetal Growth Retardation
Peroxisome proliferator-activated receptor delta suppresses 11beta-hydroxysteroid dehydrogenase type 2 gene expression in human placental trophoblast cells.
Fetal Growth Retardation
Placental 11beta-hydroxysteroid dehydrogenase type 2 is reduced in pregnancies complicated with idiopathic intrauterine growth Restriction: evidence that this is associated with an attenuated ratio of cortisone to cortisol in the umbilical artery.
Fetal Growth Retardation
Reduced placental 11beta-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms.
Fetal Growth Retardation
Renal and extrarenal mechanisms of perinatal programming after intrauterine growth restriction.
Fetal Growth Retardation
Site-specific methylation of placental HSD11B2 gene promoter is related to intrauterine growth restriction.
Fetal Growth Retardation
The 11beta-hydroxysteroid dehydrogenases: functions and physiological effects.
Fetal Growth Retardation
The cortisol-cortisone shuttle in children born with intrauterine growth retardation.
Fibrosarcoma
Characterization of 11beta-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines.
Gallstones
Estimation of ursodeoxycholic acid in human and bear biles using Clostridium absonum 7 beta-hydroxysteroid dehydrogenase.
Genetic Diseases, Inborn
A novel mutation in HSD11B2 causes apparent mineralocorticoid excess in an Omani kindred.
Gestational Trophoblastic Disease
11beta-Hydroxysteroid dehydrogenase activity in pregnancies complicated by hydatidiform mole.
Glaucoma
11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Glaucoma
11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.
Glaucoma
11{beta}-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response.
Glaucoma
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension.
Glaucoma
Type 1 11beta-hydroxysteroid dehydrogenase as universal drug target in metabolic diseases?
Glioblastoma
CTL recognition of a novel HLA-A*0201-binding peptide derived from glioblastoma multiforme tumor cells.
Glomerulonephritis
Reduced 11beta-hydroxysteroid dehydrogenase activity in patients with the nephrotic syndrome.
Glucose Intolerance
11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus.
Glucose Intolerance
Cell-type specific regulation of the human 11beta-hydroxysteroid dehydrogenase type 1 promoter.
Glucose Intolerance
Diabetic pregnancy in rats leads to impaired glucose metabolism in offspring involving tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 expression.
Glucose Intolerance
Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity.
Glucose Intolerance
Influence of placental 11beta-hydroxysteroid dehydrogenase (11beta-HSD) inhibition on glucose metabolism and 11beta-HSD regulation in adult offspring of rats.
Glucose Intolerance
Longer HSD11B2 CA-repeat in impaired glucose tolerance and type 2 diabetes.
Glucose Intolerance
Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity.
Glucose Intolerance
[Correlations between the hypothalamo-pituitary-adrenal axis and the metabolic syndrome]
Granuloma
11beta-hydroxysteroid dehydrogenases are regulated during the pulmonary granulomatous response to the mycobacterial glycolipid trehalose-6,6'-dimycolate.
Graves Ophthalmopathy
The role of 11beta-hydroxysteroid dehydrogenase 1 in adipogenesis in thyroid-associated ophthalmopathy.
HELLP Syndrome
The transplacental passage of prednisolone in pregnancies complicated by early-onset HELLP syndrome.
Herpes Zoster
Comparative enzymology of 11 beta -hydroxysteroid dehydrogenase type 1 from glucocorticoid resistant (Guinea pig) versus sensitive (human) species.
Herpes Zoster
Histochemical observations on the adrenal gland of bat Vesperugo pipistrellus (Dobson).
Herpes Zoster
Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues.
Hydatidiform Mole
11beta-Hydroxysteroid dehydrogenase activity in pregnancies complicated by hydatidiform mole.
Hyperaldosteronism
11Beta-Hydroxylase Deficiency and Other Syndromes of Mineralocorticoid Excess as a Rare Cause of Endocrine Hypertension.
Hyperaldosteronism
Induction of 11beta-hydroxysteroid dehydrogenase type 2 and hyperaldosteronism are essential for enhanced sodium absorption after total colectomy in rats.
Hyperaldosteronism
Primary aldosteronism treated by trilostane (3 beta-hydroxysteroid dehydrogenase inhibitor).
Hyperandrogenism
11beta-hydroxysteroid dehydrogenase type 1 deficiency ('apparent cortisone reductase deficiency') in a 6-year-old boy.
Hyperandrogenism
11{beta}-Hydroxysteroid Dehydrogenase Type 1 and Its Role in the Hypothalamus-Pituitary-Adrenal Axis, Metabolic Syndrome, and Inflammation.
Hyperandrogenism
A combination of polymorphisms in HSD11B1 associates with in vivo 11{beta}-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome.
Hyperandrogenism
Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome.
Hyperandrogenism
Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase.
Hyperglycemia
11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress.
Hyperglycemia
Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance.
Hyperglycemia
Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring.
Hyperglycemia
Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice.
Hyperglycemia
Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone.
Hyperglycemia
Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice.
Hyperglycemia
PPARalpha agonists reduce 11beta-hydroxysteroid dehydrogenase type 1 in the liver.
Hyperglycemia
Role of glucocorticoids in the physiopathology of excessive fat deposition and insulin resistance.
Hyperglycemia
Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice.
Hyperglycemia
The mother or the fetus? 11beta-hydroxysteroid dehydrogenase type 2 null mice provide evidence for direct fetal programming of behavior by endogenous glucocorticoids.
Hyperglycemia
Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Hyperinsulinism
Acute in vivo regulation of 11beta-hydroxysteroid dehydrogenase type 1 activity by insulin and intralipid infusions in humans.
Hyperinsulinism
MRNA and enzyme activity of hepatic 11beta-hydroxysteroid dehydrogenase type 1 are elevated in C57BL/KsJ-db/db mice.
Hyperinsulinism
Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model.
Hyperlipidemias
Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
Hyperlipidemias
Depot-specific modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11beta-hydroxysteroid dehydrogenase type 1.
Hyperlipidemias
High-throughput screening of 11beta-hydroxysteroid dehydrogenase type 1 in scintillation proximity assay format.
Hyperlipidemias
Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone.
Hyperlipidemias
Pathophysiology of metabolic syndrome X and its links to the perinatal period.
Hypertension
11?-Hydroxysteroid Dehydrogenase Type 2 Polymorphisms and Activity in a Chilean Essential Hypertensive and Normotensive Cohort.
Hypertension
11beta-hydroxysteroid dehydrogenase activity in human aortic smooth muscle cells.
Hypertension
11Beta-hydroxysteroid dehydrogenase activity in spontaneously hypertensive and Dahl rats.
Hypertension
11beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
Hypertension
11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.
Hypertension
11beta-hydroxysteroid dehydrogenase in cultured human vascular cells. Possible role in the development of hypertension.
Hypertension
A case of pseudoaldosteronism, accompanied with hypocalcemia and exaggerated ACTH response.
Hypertension
A combination of polymorphisms in HSD11B1 associates with in vivo 11{beta}-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome.
Hypertension
A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension.
Hypertension
A new polymorphic restriction site in the human 11 beta-hydroxysteroid dehydrogenase type 2 gene.
Hypertension
A novel mutation in HSD11B2 causes apparent mineralocorticoid excess in an Omani kindred.
Hypertension
A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): flavanone selectively inhibits 11beta-HSD1 reductase activity.
Hypertension
A urine-concentrating defect in 11?-hydroxysteroid dehydrogenase type 2 null mice.
Hypertension
Acute intrarenal administration of cortisol has no effect on renal blood flow in hypertensive individuals.
Hypertension
Age-dependent decrease in 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) activity in hypertensive patients.
Hypertension
Analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene (HSD11B2) in human essential hypertension.
Hypertension
Angiotensin II regulates 11beta-hydroxysteroid dehydrogenase type 2 via AT2 receptors.
Hypertension
Apparent Mineralocorticoid Excess by a Novel Mutation and Epigenetic Modulation by HSD11B2 Promoter Methylation.
Hypertension
Apparent mineralocorticoid excess caused by novel compound heterozygous mutations in HSD11B2 and characterized by early-onset hypertension and hypokalemia.
Hypertension
Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state.
Hypertension
Apparent mineralocorticoid excess: report of six new cases and extensive personal experience.
Hypertension
Arginine vasopressin stimulates 11beta-hydroxysteroid dehydrogenase type 2 expression in the mineralocorticosteroid target cells.
Hypertension
Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure.
Hypertension
Association of HSD11B1 gene polymorphisms with type 2 diabetes and metabolic syndrome in South Indian population.
Hypertension
Biochemical and genetic characterization of 11 beta-hydroxysteroid dehydrogenase type 2 in low-renin essential hypertensives.
Hypertension
CA-Repeat polymorphism in intron 1 of HSD11B2 : effects on gene expression and salt sensitivity.
Hypertension
Carbenoxolone damages endothelium and enhances vasoconstrictor action in aortic rings.
Hypertension
Chronic hypoxemia selectively down-regulates 11beta-hydroxysteroid dehydrogenase type 2 gene expression in the fetal sheep kidney.
Hypertension
Cloning and expression of rat cDNA encoding corticosteroid 11 beta-dehydrogenase.
Hypertension
Common Variation at the 11-Beta Hydroxysteroid Dehydrogenase Type 1 (HSD11B1) Gene Is Associated with Left Ventricular Mass.
Hypertension
Conditional Deletion of Hsd11b2 in the Brain Causes Salt Appetite and Hypertension.
Hypertension
Detection of Urinary Exosomal HSD11B2 mRNA Expression: A Useful Novel Tool for the Diagnostic Approach of Dysfunctional 11?-HSD2-Related Hypertension.
Hypertension
Developmental programming of renal glucocorticoid sensitivity and the renin-angiotensin system.
Hypertension
Effect of immunosuppressive and other drugs on the cortisol-cortisone shuttle in human kidney and liver.
Hypertension
Effects of alcohol on blood pressure and production of vascular aldosterone and corticosterone.
Hypertension
Effects of cholic acid on blood pressure and production of vascular aldosterone and corticosterone.
Hypertension
Effects of glucose on blood pressure and production of vascular aldosterone and corticosterone.
Hypertension
Effects of glycyrrhizin on production of vascular aldosterone and corticosterone.
Hypertension
Effects of spironolactone on systolic blood pressure in experimental diabetic rats.
Hypertension
Endothelial cell dysfunction in mice after transgenic knockout of type 2, but not type 1, 11beta-hydroxysteroid dehydrogenase.
Hypertension
Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide.
Hypertension
Enhanced 11beta-hydroxysteroid dehydrogenase activity, the metabolic syndrome, and systemic hypertension.
Hypertension
Epigenetic control of 11 beta-hydroxysteroid dehydrogenase 2 gene promoter is related to human hypertension.
Hypertension
Epigenetic regulation of 11 beta-hydroxysteroid dehydrogenase type 2 expression.
Hypertension
Evidence of altered cortisol metabolism in critically ill patients: a prospective study.
Hypertension
Expression of renal 11beta-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function.
Hypertension
Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
Hypertension
Extracellular ATP determines 11beta-hydroxysteroid dehydrogenase type 2 activity via purinergic receptors.
Hypertension
Functional adrenocorticotropic hormone receptor in cultured human vascular endothelial cells : possible role in control of blood pressure.
Hypertension
Functional effects of polymorphisms in the human gene encoding 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1): a sequence variant at the translation start of 11 beta-HSD1 alters enzyme levels.
Hypertension
Gene expression of 11beta-hydroxysteroid dehydrogenase type 1 and type 2 in the kidneys of insulin-dependent diabetic rats.
Hypertension
Genetic association of 11 beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks.
Hypertension
Genetic variations of HSD11B2 in hypertensive patients and in the general population, six rare missense/frameshift mutations.
Hypertension
Genotype-phenotype correlations of mutations and polymorphisms in HSD11B2, the gene encoding the kidney isozyme of 11beta-hydroxysteroid dehydrogenase.
Hypertension
Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension.
Hypertension
Glycyrrhetinic acid attenuates vascular smooth muscle vasodilatory function in healthy humans.
Hypertension
Glycyrrhetinic acid decreases plasma potassium concentrations in patients with anuria.
Hypertension
Herbal Medicine Containing Licorice May Be Contraindicated for a Patient With an HSD11B2 Mutation.
Hypertension
HSD11B2, RUNX3, and LINE-1 Methylation in Placental DNA of Hypertensive Disorders of Pregnancy Patients.
Hypertension
Hypertension and circulating mRNA for 11beta-hydroxysteroid dehydrogenase type II.
Hypertension
Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess.
Hypertension
In vivo 11beta-HSD-2 activity: variability, salt-sensitivity, and effect of licorice.
Hypertension
Influence of aldosterone vs. endothelin receptor antagonism on renovascular function in liquorice-induced hypertension.
Hypertension
Inhibition of 11-beta-hydroxysteroid dehydrogenase in pregnant rats and the programming of blood pressure in the offspring.
Hypertension
Interaction between an 11betaHSD1 gene variant and birth era modifies the risk of hypertension in Pima Indians.
Hypertension
Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene.
Hypertension
Licorice-induced hypertension and common variants of genes regulating renal sodium reabsorption.
Hypertension
Maintenance of maternal diet-induced hypertension in the rat is dependent on glucocorticoids.
Hypertension
Maternal hypertension and progeny blood pressure: role of aldosterone and 11beta-HSD.
Hypertension
Mechanism of hypertension in Cushing's syndrome: possible role of 11beta-hydroxysteroid dehydrogenase type 2 in kidneys and vascular cells.
Hypertension
Medical and physiological aspects of the 11beta-hydroxysteroid dehydrogenase system.
Hypertension
Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Hypertension
Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess.
Hypertension
Molecular basis for the apparent mineralocorticoid excess syndrome in the Oman population.
Hypertension
Molecular determinants of the adrenal gland functioning related to stress-sensitive hypertension in ISIAH rats.
Hypertension
Mutations in the 11 beta-hydroxysteroid dehydrogenase type II enzyme associated with hypertension and possibly stillbirth.
Hypertension
Phenotypic analysis of mice bearing targeted deletions of 11beta-hydroxysteroid dehydrogenases 1 and 2 genes.
Hypertension
Possible association but no linkage of the HSD11B2 gene encoding the kidney isozyme of 11beta-hydroxysteroid dehydrogenase to hypertension in Black people.
Hypertension
Quantitative real-time PCR for the measurement of 11beta-HSD1 and 11beta-HSD2 mRNA levels in tissues of healthy dogs.
Hypertension
Reduced levels of circulating 7alpha-hydroxy-dehydroepiandrosterone in treated adolescent obese patients.
Hypertension
Regulation of 11beta-hydroxysteroid dehydrogenase type 2 by diuretics and the renin-angiotensin-aldosterone axis.
Hypertension
Renal Dysfunction Induced by Kidney-Specific Gene Deletion of Hsd11b2 as a Primary Cause of Salt-Dependent Hypertension.
Hypertension
Renal interstitial corticosterone and 11-dehydrocorticosterone in conscious rats.
Hypertension
Renal medullary 11 beta-hydroxysteroid dehydrogenase type 1 in Dahl salt-sensitive hypertension.
Hypertension
Role of HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides.
Hypertension
Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation.
Hypertension
Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches.
Hypertension
Salt-sensitive men show reduced heart rate variability, lower norepinephrine and enhanced cortisol during mental stress.
Hypertension
Spironolactone effective hypertension in the elderly due to 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) impairment: contributory role of determining serum cortisol/cortisone ratio as a marker of 11beta-HSD2 activity.
Hypertension
Structural analysis and evaluation of the 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) gene in human essential hypertension.
Hypertension
Structural analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene in end-stage renal disease.
Hypertension
Structure of the VPATPD gene encoding subunit D of the human vacuolar proton ATPase.
Hypertension
The (+)- and (-)-gossypols potently inhibit human and rat 11beta-hydroxysteroid dehydrogenase type 2.
Hypertension
The 11beta-hydroxysteroid dehydrogenases: functions and physiological effects.
Hypertension
The cortisol-cortisone shuttle in children born with intrauterine growth retardation.
Hypertension
The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
Hypertension
The hypertensiogenetic steroid 19-nor-progesterone does not influence cortisol inactivation by 11beta-hydroxysteroid dehydrogenase type 2.
Hypertension
The maternal diet during pregnancy programs altered expression of the glucocorticoid receptor and type 2 11beta-hydroxysteroid dehydrogenase: potential molecular mechanisms underlying the programming of hypertension in utero.
Hypertension
The mother or the fetus? 11beta-hydroxysteroid dehydrogenase type 2 null mice provide evidence for direct fetal programming of behavior by endogenous glucocorticoids.
Hypertension
The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension.
Hypertension
Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action.
Hypertension
Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Hypertension
Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.
Hypertension
Variation in placental type 2 11beta-hydroxysteroid dehydrogenase activity is not related to birth weight or placental weight.
Hypertension
[Possible pathogenetic role of 11 beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) gene polymorphisms in arterial hypertension]
Hypertension
[The activity of 11beta-hydroxysteroid dehydrogenase of rat kidney and liver at inherited stress-induced arterial hypertension]
Hypertension, Pregnancy-Induced
Alteration of the activity of the 11beta-hydroxysteroid dehydrogenase in pregnancy: relevance for the development of pregnancy-induced hypertension?
Hypertension, Pregnancy-Induced
HSD11B2, RUNX3, and LINE-1 Methylation in Placental DNA of Hypertensive Disorders of Pregnancy Patients.
Hyperthyroidism
Comprehensive study of urinary cortisol metabolites in hyperthyroid and hypothyroid patients.
Hypertriglyceridemia
11beta-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues.
Hypertrophy, Left Ventricular
Sexually dimorphic effects of maternal alcohol intake and adrenalectomy on left ventricular hypertrophy in rat offspring.
Hypoglycemia
Deletion of Hexose-6-phosphate Dehydrogenase Activates the Unfolded Protein Response Pathway and Induces Skeletal Myopathy.
Hypokalemia
Apparent mineralocorticoid excess caused by novel compound heterozygous mutations in HSD11B2 and characterized by early-onset hypertension and hypokalemia.
Hypokalemia
Correlation between decrease of 11beta-hydroxysteroid dehydrogenase activity and hypokalemia induced by furosemide in rats.
Hypokalemia
Genetic variations of HSD11B2 in hypertensive patients and in the general population, six rare missense/frameshift mutations.
Hypokalemia
Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess.
Hypokalemia
Persistent hypokalemia after successful adrenalectomy in a patient with Cushing's syndrome due to ectopic ACTH secretion: possible role of 11beta-hydroxysteroid dehydrogenase inhibition.
Hypokalemia
Phenotypic analysis of mice bearing targeted deletions of 11beta-hydroxysteroid dehydrogenases 1 and 2 genes.
Hypokalemia
Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation.
Hypokalemia
Severe muscle weakness due to hypokalemia as a manifestation of small-cell carcinoma.
Hypokalemia
The (+)- and (-)-gossypols potently inhibit human and rat 11beta-hydroxysteroid dehydrogenase type 2.
Hypophosphatemia, Familial
Transcriptional and physiological responses to chronic ACTH treatment by the mouse kidney.
Hypopituitarism
Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle.
Hypopituitarism
Lack of contribution of 11betaHSD1 and glucocorticoid action to reduced muscle mass associated with reduced growth hormone action.
Hypopituitarism
Lack of regulation of 11beta-hydroxysteroid dehydrogenase type 1 during short-term manipulation of GH in patients with hypopituitarism.
Hypotension
Placental 11beta-HSD2 activity, early postnatal clinical course, and adrenal function in extremely low birth weight infants.
Hypothyroidism
Effects of thyroid hormone (thyroxine) and testosterone on hepatic 11beta-hydroxysteroid dehydrogenase mRNA and activity in pubertal hypothyroid male rats.
Hypothyroidism
Sex-specific effects of growth hormone on hepatic 11beta-hydroxysteroid dehydrogenase activity and gene expression in hypothyroid rats.
Infections
Aeromonas hydrophila infection in silver catfish causes hyperlocomotion related to stress.
Infections
Clinical outcome in anti-neutrophil cytoplasmic antibody-associated vasculitis and gene variants of 11?-hydroxysteroid dehydrogenase type 1 and the glucocorticoid receptor.
Infections
Effect of pro-inflammatory cytokines on expression and activity of 11beta-hydroxysteroid dehydrogenase type 2 in cultured human term placental trophoblast and human choriocarcinoma JEG-3 cells.
Infections
Enhancement of cortisol-induced 11beta-hydroxysteroid dehydrogenase type 1 expression by interleukin 1beta in cultured human chorionic trophoblast cells.
Infections
Stimulation of 11beta-HSD1 expression by IL-1beta via a C/EBP binding site in human fetal lung fibroblasts.
Infertility, Male
Transcriptional alterations of genes related to fertility decline in male rats induced by chronic sleep restriction.
Inflammatory Bowel Diseases
11beta-hydroxysteroid dehydrogenase 1 and 2 expression in colon from patients with ulcerative colitis.
Inflammatory Bowel Diseases
Expression profiles of human 11beta-hydroxysteroid dehydrogenases type 1 and type 2 in inflammatory bowel diseases.
Inflammatory Bowel Diseases
Type II 11beta-hydroxysteroid dehydrogenase expression in human colonic epithelial cells of inflammatory bowel disease.
Inflammatory Bowel Diseases
Upregulation of 11?-hydroxysteroid dehydrogenase 1 in lymphoid organs during inflammation in the rat.
Insulin Resistance
11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Insulin Resistance
11beta-hydroxysteroid dehydrogenase 2 activity is elevated in severe obesity and negatively associated with insulin sensitivity.
Insulin Resistance
11beta-hydroxysteroid dehydrogenase activity in acromegalic patients with normal or impaired carbohydrate metabolism.
Insulin Resistance
11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.
Insulin Resistance
11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus.
Insulin Resistance
11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue and prospective changes in body weight and insulin resistance.
Insulin Resistance
11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Insulin Resistance
11beta-Hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
Insulin Resistance
11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.
Insulin Resistance
11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents.
Insulin Resistance
11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients.
Insulin Resistance
11{beta}-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle.
Insulin Resistance
4-(Phenylsulfonamidomethyl)benzamides as potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1 with efficacy in diabetic ob/ob mice.
Insulin Resistance
Adipose tissue expression of 11beta-hydroxysteroid dehydrogenase type 1 in Cushing's syndrome and in obesity.
Insulin Resistance
Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.
Insulin Resistance
Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
Insulin Resistance
Association between 11beta-hydroxysteroid dehydrogenase type 1 gene polymorphisms and metabolic syndrome in Bosnian population.
Insulin Resistance
Association of HSD11B1 gene polymorphisms with type 2 diabetes and metabolic syndrome in South Indian population.
Insulin Resistance
Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase.
Insulin Resistance
Cortisol metabolism in healthy young adults: sexual dimorphism in activities of A-ring reductases, but not 11beta-hydroxysteroid dehydrogenases.
Insulin Resistance
Cortisol metabolism in human obesity: impaired cortisone-->cortisol conversion in subjects with central adiposity.
Insulin Resistance
Cortisone induces insulin resistance in C2C12 myotubes through activation of 11beta-hydroxysteroid dehydrogenase 1 and autocrinal regulation.
Insulin Resistance
Deletion of Hexose-6-phosphate Dehydrogenase Activates the Unfolded Protein Response Pathway and Induces Skeletal Myopathy.
Insulin Resistance
Diabetic pregnancy in rats leads to impaired glucose metabolism in offspring involving tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 expression.
Insulin Resistance
Diet-induced weight loss alters hepatic glucocorticoid metabolism in type 2 diabetes mellitus.
Insulin Resistance
Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.
Insulin Resistance
Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Insulin Resistance
Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Insulin Resistance
Ectopic lipid deposition mediates insulin resistance in adipose specific 11?-Hydroxysteroid dehydrogenase type 1 transgenic mice.
Insulin Resistance
Effect of voluntary exercise on peripheral tissue glucocorticoid receptor content and the expression and activity of 11beta-HSD1 in the Syrian hamster.
Insulin Resistance
Effects of a high-salt diet on adipocyte glucocorticoid receptor and 11-beta hydroxysteroid dehydrogenase 1 in salt-sensitive hypertensive rats.
Insulin Resistance
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
Insulin Resistance
Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice.
Insulin Resistance
Enhanced cortisol production rates, free cortisol, and 11beta-HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss.
Insulin Resistance
Expression of 11beta-hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome.
Insulin Resistance
Gender-specific links between hepatic 11beta reduction of cortisone and adipokines.
Insulin Resistance
Glucocorticoid metabolism within superficial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women.
Insulin Resistance
Glucocorticoid receptor gene expression in adipose tissue and associated metabolic risk in black and white South African women.
Insulin Resistance
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic sindrome.
Insulin Resistance
Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle.
Insulin Resistance
H6PDH interacts directly with 11beta-HSD1: implications for determining the directionality of glucocorticoid catalysis.
Insulin Resistance
Hepatic glucose regulation and metabolism in adult sheep: effects of prenatal betamethasone.
Insulin Resistance
Immortalization of Porcine 11?-Hydroxysteroid Dehydrogenase Type 1-Transgenic Liver Cells Using SV40 Large T Antigen.
Insulin Resistance
Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity.
Insulin Resistance
Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice.
Insulin Resistance
In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue.
Insulin Resistance
In vivo activity of 11beta-hydroxysteroid dehydrogenase type 1 and free fatty acid-induced insulin resistance.
Insulin Resistance
Increased glucocorticoid receptor and 11{beta}-hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db/db mice.
Insulin Resistance
Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome.
Insulin Resistance
Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone.
Insulin Resistance
Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome.
Insulin Resistance
Interactions between oestradiol and glucocorticoid regulatory effects on liver-specific glucocorticoid-inducible genes: possible evidence for a role of hepatic 11beta-hydroxysteroid dehydrogenase type 1.
Insulin Resistance
Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats.
Insulin Resistance
Lack of relationship between 11beta-hydroxysteroid dehydrogenase setpoint and insulin sensitivity in the basal state and after 24h of insulin infusion in healthy subjects and type 2 diabetic patients.
Insulin Resistance
Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice.
Insulin Resistance
Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity.
Insulin Resistance
Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.
Insulin Resistance
Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Insulin Resistance
Minireview: hexose-6-phosphate dehydrogenase and redox control of 11{beta}-hydroxysteroid dehydrogenase type 1 activity.
Insulin Resistance
Modulation of susceptibility to weight gain and insulin resistance in low birthweight rats by treatment of their mothers with leptin during pregnancy and lactation.
Insulin Resistance
Molecular determinants of the adrenal gland functioning related to stress-sensitive hypertension in ISIAH rats.
Insulin Resistance
MRNA and enzyme activity of hepatic 11beta-hydroxysteroid dehydrogenase type 1 are elevated in C57BL/KsJ-db/db mice.
Insulin Resistance
Overexpression of 11beta-Hydroxysteroid Dehydrogenase Type 1 in Hepatic and Visceral Adipose Tissue is Associated with Metabolic Disorders in Morbidly Obese Patients.
Insulin Resistance
Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins.
Insulin Resistance
Pathophysiology of metabolic syndrome X and its links to the perinatal period.
Insulin Resistance
Physiological roles of 11 beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase.
Insulin Resistance
Population Pharmacokinetic/Pharmacodynamic Model of Subcutaneous Adipose 11{beta}-Hydroxysteroid Dehydrogenase Type 1 (11{beta}-HSD1) Activity After Oral Administration of AMG 221, a Selective 11{beta}-HSD1 Inhibitor.
Insulin Resistance
Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity?
Insulin Resistance
Reduced 11beta-hydroxysteroid dehydrogenase type 1 activity in obese boys.
Insulin Resistance
Reduced glucocorticoid production rate, decreased 5alpha-reductase activity, and adipose tissue insulin sensitization after weight loss.
Insulin Resistance
Reduced levels of circulating 7alpha-hydroxy-dehydroepiandrosterone in treated adolescent obese patients.
Insulin Resistance
Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss.
Insulin Resistance
Regulation of glucocorticoid receptor alpha and beta isoforms and type I 11beta-hydroxysteroid dehydrogenase expression in human skeletal muscle cells: a key role in the pathogenesis of insulin resistance?
Insulin Resistance
Rosiglitazone decreases 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue.
Insulin Resistance
Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains.
Insulin Resistance
Several obesity- and nutrient-related gene polymorphisms but not FTO and UCP variants modulate postabsorptive resting energy expenditure and fat-induced thermogenesis in obese individuals: the NUGENOB Study.
Insulin Resistance
Skeletal muscle 11beta-HSD1 controls glucocorticoid-induced proteolysis and expression of E3 ubiquitin ligases atrogin-1 and MuRF-1.
Insulin Resistance
Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.
Insulin Resistance
Subcutaneous Abdominal Adipose Tissue Subcompartments: Potential Role in Rosiglitazone Effects.
Insulin Resistance
The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans.
Insulin Resistance
The critical role of the N-terminus of 11beta-hydroxysteroid dehydrogenase type 1, as being encoded by exon 1, for enzyme stabilization and activity.
Insulin Resistance
The Role of 11Beta-Hydroxysteroid Dehydrogenase in Metabolic Disease and Therapeutic Potential of 11Beta-HSD1 Inhibitors.
Insulin Resistance
Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity.
Insulin Resistance
Tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 and pathogenesis of the metabolic syndrome.
Insulin Resistance
Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Insulin Resistance
Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.
Insulin Resistance
Variants in HSD11B1 gene modulate susceptibility to diabetes kidney disease and to insulin resistance in type 1 diabetes.
Insulin Resistance
Weight loss increases 11beta-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue.
Kidney Diseases
Variants in HSD11B1 gene modulate susceptibility to diabetes kidney disease and to insulin resistance in type 1 diabetes.
Kidney Failure, Chronic
A new polymorphic restriction site in the human 11 beta-hydroxysteroid dehydrogenase type 2 gene.
Kidney Failure, Chronic
Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure.
Kidney Failure, Chronic
Genetic association of 11 beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks.
Kidney Failure, Chronic
Pediatric renal allograft transplantation does not normalize the increased cortisol/cortisone ratios of chronic renal failure.
Kidney Failure, Chronic
Role of 11beta-hydroxysteroid dehydrogenase 2 renal activity in potassium homeostasis in rats with chronic renal failure.
Kidney Failure, Chronic
Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation.
Kidney Failure, Chronic
Structural analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene in end-stage renal disease.
Kidney Failure, Chronic
The role of 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension.
Leprosy
Alteration of the cortisol-cortisone shuttle in leprosy type 1 reactions in leprosy patients in Hyderabad, India.
Leukemia
Differential regulation of 11beta-hydroxysteroid dehydrogenase-1 by dexamethasone in glucocorticoid-sensitive and -resistant childhood lymphoblastic leukemia.
Leukemia
Meeting Report:The 7th ESPE Growth Plate Working Group Symposium - EUROGROP June 27th 2007, Helsinki, Finland.
Liddle Syndrome
Down-regulation of a hepatic transporter multidrug resistance-associated protein 2 is involved in alteration of pharmacokinetics of glycyrrhizin and its metabolites in a rat model of chronic liver injury.
Lipodystrophy
In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue.
Liver Cirrhosis
11Beta-hydroxysteroid dehydrogenase-1 deficiency or inhibition enhances hepatic myofibroblast activation in murine liver fibrosis.
Liver Cirrhosis
Biphasic changes of epithelial sodium channel abundance and trafficking in common bile duct ligation-induced liver cirrhosis.
Liver Cirrhosis
Down-regulation of a hepatic transporter multidrug resistance-associated protein 2 is involved in alteration of pharmacokinetics of glycyrrhizin and its metabolites in a rat model of chronic liver injury.
Liver Cirrhosis
Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension.
Liver Cirrhosis
Increased apical targeting of renal epithelial sodium channel subunits and decreased expression of type 2 11beta-hydroxysteroid dehydrogenase in rats with CCl4-induced decompensated liver cirrhosis.
Liver Cirrhosis
Renal sodium retention in cirrhotic rats depends on glucocorticoid-mediated activation of mineralocorticoid receptor due to decreased renal 11beta-HSD-2 activity.
Liver Diseases
Induction of hepatic 11beta-hydroxysteroid dehydrogenase type 1 in patients with alcoholic liver disease.
Liver Diseases, Alcoholic
Induction of hepatic 11beta-hydroxysteroid dehydrogenase type 1 in patients with alcoholic liver disease.
Lung Neoplasms
11Beta-hydroxysteroid dehydrogenase 1 expression in squamous cell carcinomas of the head and neck.
Lung Neoplasms
Expression of 11beta-hydroxysteroid dehydrogenase type 2 in an ACTH-producing small cell lung cancer.
Lung Neoplasms
Interindividual variability in the expression and NNK carbonyl reductase activity of 11beta-hydroxysteroid dehydrogenase 1 in human lung.
Lung Neoplasms
Purification, characterization and NNK carbonyl reductase activities of 11beta-hydroxysteroid dehydrogenase type 1 from human liver: enzyme cooperativity and significance in the detoxification of a tobacco-derived carcinogen.
Malnutrition
Fetal exposure to excess glucocorticoid is unlikely to explain the effects of periconceptional undernutrition in sheep.
Malnutrition
Maternal undernutrition during early to midgestation programs tissue-specific alterations in the expression of the glucocorticoid receptor, 11beta-hydroxysteroid dehydrogenase isoforms, and type 1 angiotensin ii receptor in neonatal sheep.
Malnutrition
Perinatal maternal undernutrition programs the offspring hypothalamo-pituitary-adrenal (HPA) axis.
Menorrhagia
Cortisol inactivation by 11beta-hydroxysteroid dehydrogenase-2 may enhance endometrial angiogenesis via reduced thrombospondin-1 in heavy menstruation.
Metabolic Diseases
11beta-HSD1, inflammation, metabolic disease and age-related cognitive (dys)function.
Metabolic Diseases
11beta-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation.
Metabolic Diseases
A Polygenic Model of the Metabolic Syndrome With Reduced Circulating and Intra-Adipose Glucocorticoid Action.
Metabolic Diseases
Alteration in methylation level at 11?-hydroxysteroid dehydrogenase type 2 gene promoter in infants born to preeclamptic women.
Metabolic Diseases
Benzothiazole derivatives as novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Metabolic Diseases
Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys.
Metabolic Diseases
Development of a high-throughput cell-based assay for 11beta-hydroxysteroid dehydrogenase type 1 using BacMam technology.
Metabolic Diseases
Diabetic pregnancy in rats leads to impaired glucose metabolism in offspring involving tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 expression.
Metabolic Diseases
Down-regulation of adipose 11beta-hydroxysteroid dehydrogenase type 1 by high-fat feeding in mice: a potential adaptive mechanism counteracting metabolic disease.
Metabolic Diseases
Fructose consumption enhances glucocorticoid action in rat visceral adipose tissue.
Metabolic Diseases
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic sindrome.
Metabolic Diseases
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 by plant extracts used as traditional antidiabetic medicines.
Metabolic Diseases
Inhibition of human and rat 11beta-hydroxysteroid dehydrogenase type 1 by 18beta-glycyrrhetinic acid derivatives.
Metabolic Diseases
Modulation of 11beta-hydroxysteroid dehydrogenase type 1 activity by 1,5-substituted 1H-tetrazoles.
Metabolic Diseases
Obesity and Corticosteroids: 11beta-Hydroxysteroid Type 1 as a Cause and Therapeutic Target in Metabolic Disease.
Metabolic Diseases
Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches.
Metabolic Diseases
Selection and optimization of MCF-7 cell line for screening selective inhibitors of 11beta-hydroxysteroid dehydrogenase 2.
Metabolic Diseases
Selective inhibition of 11beta-hydroxysteroid dehydrogenase 1 by 18alpha-glycyrrhetinic acid but not 18beta-glycyrrhetinic acid.
Metabolic Diseases
The role and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in the inflammatory response.
Metabolic Diseases
The Role of 11Beta-Hydroxysteroid Dehydrogenase in Metabolic Disease and Therapeutic Potential of 11Beta-HSD1 Inhibitors.
Metabolic Diseases
Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.
Metabolic Diseases
Type 1 11beta-hydroxysteroid dehydrogenase as universal drug target in metabolic diseases?
Metabolic Syndrome
11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Metabolic Syndrome
11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity.
Metabolic Syndrome
11?-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Metabolic Syndrome
11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization.
Metabolic Syndrome
11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.
Metabolic Syndrome
11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational approaches.
Metabolic Syndrome
11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory.
Metabolic Syndrome
11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease.
Metabolic Syndrome
11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Metabolic Syndrome
11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes.
Metabolic Syndrome
11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
Metabolic Syndrome
11beta-Hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
Metabolic Syndrome
11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.
Metabolic Syndrome
11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents.
Metabolic Syndrome
11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Metabolic Syndrome
11beta-Hydroxysteroid Dehydrogenase Type 1 is Overexpressed in Subcutaneous Adipose Tissue of Morbidly Obese Patients.
Metabolic Syndrome
11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients.
Metabolic Syndrome
11beta-hydroxysteroid dehydrogenase type 1 of the subcutaneous adipose tissue is dysregulated but not associated with metabolic disorders in adults born small for gestational age.
Metabolic Syndrome
11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.
Metabolic Syndrome
11Beta-hydroxysteroid dehydrogenase-1 deficiency or inhibition enhances hepatic myofibroblast activation in murine liver fibrosis.
Metabolic Syndrome
11{beta}-Hydroxysteroid Dehydrogenase Type 1 and Its Role in the Hypothalamus-Pituitary-Adrenal Axis, Metabolic Syndrome, and Inflammation.
Metabolic Syndrome
11{beta}-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response.
Metabolic Syndrome
2-(S)-phenethylaminothiazolones as potent, orally efficacious inhibitors of 11beta-hydroxysteriod dehydrogenase type 1.
Metabolic Syndrome
2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
Metabolic Syndrome
7-oxysterols modulate glucocorticoid activity in adipocytes through competition for 11beta-hydroxysteroid dehydrogenase type.
Metabolic Syndrome
A combination of polymorphisms in HSD11B1 associates with in vivo 11{beta}-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome.
Metabolic Syndrome
A novel promoter for the 11beta-hydroxysteroid dehydrogenase type 1 gene is active in lung and is C/EBPalpha independent.
Metabolic Syndrome
A Polygenic Model of the Metabolic Syndrome With Reduced Circulating and Intra-Adipose Glucocorticoid Action.
Metabolic Syndrome
Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity.
Metabolic Syndrome
Analysis of alternative promoter usage in expression of HSD11B1 including the development of a transcript-specific quantitative real-time PCR method.
Metabolic Syndrome
Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
Metabolic Syndrome
Association between 11beta-hydroxysteroid dehydrogenase type 1 gene polymorphisms and metabolic syndrome in Bosnian population.
Metabolic Syndrome
Association Between a 11?-Hydroxysteroid Dehydrogenase Type 1 Gene Polymorphism and Metabolic Syndrome in a South Indian Population.
Metabolic Syndrome
Association of HSD11B1 gene polymorphisms with type 2 diabetes and metabolic syndrome in South Indian population.
Metabolic Syndrome
Association of HSD11B1 polymorphic variants and adipose tissue gene expression with metabolic syndrome, obesity and type 2 diabetes mellitus: a systematic review.
Metabolic Syndrome
Association study of 11beta-hydroxysteroid dehydrogenase type 1 gene polymorphisms and metabolic syndrome in urban Japanese cohort.
Metabolic Syndrome
beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action.
Metabolic Syndrome
Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
Metabolic Syndrome
Cell-based assay for screening 11beta-hydroxysteroid dehydrogenase 1 inhibitors.
Metabolic Syndrome
Cell-type specific regulation of the human 11beta-hydroxysteroid dehydrogenase type 1 promoter.
Metabolic Syndrome
Characterisation of 11beta-hydroxysteroid dehydrogenase 1 in human orbital adipose tissue: a comparison with subcutaneous and omental fat.
Metabolic Syndrome
Charting biologically relevant chemical space: a structural classification of natural products (SCONP).
Metabolic Syndrome
Circulating 11beta-hydroxysteroid dehydrogenase type 1 mRNA and cardiovascular risk factors.
Metabolic Syndrome
Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species.
Metabolic Syndrome
Comparison of a homology model and the crystallographic structure of human 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) in a structure-based identification of inhibitors.
Metabolic Syndrome
Cooperativity between 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase is based on a common pyridine nucleotide pool in the lumen of the endoplasmic reticulum.
Metabolic Syndrome
Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys.
Metabolic Syndrome
Development and application of a scintillation proximity assay (SPA) for identification of selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
Metabolic Syndrome
Diabetic pregnancy in rats leads to impaired glucose metabolism in offspring involving tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 expression.
Metabolic Syndrome
Diazepane-acetamide derivatives as selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Metabolic Syndrome
Different expression and distribution of 11beta-hydroxysteroid dehydrogenase type 1 in obese and lean animal models of type 2 diabetes.
Metabolic Syndrome
Different responsiveness in body weight and hepatic 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 1 mrna to 11beta-HSD inhibition by glycyrrhetinic acid treatment in obese and lean zucker rats.
Metabolic Syndrome
Differential modulation of 3T3-L1 adipogenesis mediated by 11beta-hydroxysteroid dehydrogenase-1 levels.
Metabolic Syndrome
Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11beta-HSD1: novel therapeutic agents for the treatment of metabolic syndrome.
Metabolic Syndrome
Discovery of novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling.
Metabolic Syndrome
Discovery of potent and selective inhibitors of 11beta-HSD1 for the treatment of metabolic syndrome.
Metabolic Syndrome
Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Metabolic Syndrome
Down-regulation of adipose 11beta-hydroxysteroid dehydrogenase type 1 by high-fat feeding in mice: a potential adaptive mechanism counteracting metabolic disease.
Metabolic Syndrome
Dysregulation of 11beta-hydroxysteroid dehydrogenases: implications during pregnancy and beyond.
Metabolic Syndrome
Effect of voluntary exercise on peripheral tissue glucocorticoid receptor content and the expression and activity of 11beta-HSD1 in the Syrian hamster.
Metabolic Syndrome
Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice.
Metabolic Syndrome
Enhanced 11beta-hydroxysteroid dehydrogenase activity, the metabolic syndrome, and systemic hypertension.
Metabolic Syndrome
Enzymology and molecular biology of glucocorticoid metabolism in humans.
Metabolic Syndrome
Evidence of altered cortisol metabolism in critically ill patients: a prospective study.
Metabolic Syndrome
Functional effects of polymorphisms in the human gene encoding 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1): a sequence variant at the translation start of 11 beta-HSD1 alters enzyme levels.
Metabolic Syndrome
Gender-dependent association of HSD11B1 single nucleotide polymorphisms with glucose and HDL-C levels.
Metabolic Syndrome
Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome.
Metabolic Syndrome
Global 11 Beta-Hydroxysteroid Dehydrogenase Activity Assessed by the Circulating Cortisol to Cortisone Ratio is Associated with Features of Metabolic Syndrome.
Metabolic Syndrome
Glucocorticoid metabolism within superficial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women.
Metabolic Syndrome
Glucocorticoid regulation of the promoter of 11beta-hydroxysteroid dehydrogenase type 1 is indirect and requires CCAAT/enhancer-binding protein-beta.
Metabolic Syndrome
Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension.
Metabolic Syndrome
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue.
Metabolic Syndrome
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic sindrome.
Metabolic Syndrome
Hexose-6-phosphate dehydrogenase knock-out mice lack 11 beta-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation.
Metabolic Syndrome
High capacity homogeneous non-radioactive cortisol detection assays for human 11beta-hydroxysteroid dehydrogenase type 1.
Metabolic Syndrome
Immortalization of Porcine 11?-Hydroxysteroid Dehydrogenase Type 1-Transgenic Liver Cells Using SV40 Large T Antigen.
Metabolic Syndrome
Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments.
Metabolic Syndrome
Inhibition of 11beta-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role?
Metabolic Syndrome
Inhibition of human and rat 11beta-hydroxysteroid dehydrogenase type 1 by 18beta-glycyrrhetinic acid derivatives.
Metabolic Syndrome
Inhibitors of 11beta-HSD1: a potential treatment for the metabolic syndrome.
Metabolic Syndrome
Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome.
Metabolic Syndrome
Insulin and dexamethasone dynamically regulate adipocyte 11beta-hydroxysteroid dehydrogenase type 1.
Metabolic Syndrome
Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
Metabolic Syndrome
Lack of association of the 11 beta-hydroxysteroid dehydrogenase type 1 gene 25669dupA polymorphism with obesity and metabolic syndrome.
Metabolic Syndrome
Liver X receptors downregulate 11beta-hydroxysteroid dehydrogenase type 1 expression and activity.
Metabolic Syndrome
Local metabolism of glucocorticoids in Prague hereditary hypertriglyceridemic rats - Effect of hypertriglyceridemia and gender.
Metabolic Syndrome
Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.
Metabolic Syndrome
Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Metabolic Syndrome
Minireview: hexose-6-phosphate dehydrogenase and redox control of 11{beta}-hydroxysteroid dehydrogenase type 1 activity.
Metabolic Syndrome
Molecular screening of the 11beta-HSD1 gene in men characterized by the metabolic syndrome.
Metabolic Syndrome
Novel non-steroidal inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Metabolic Syndrome
Omental 11beta-hydroxysteroid dehydrogenase 1 correlates with fat cell size independently of obesity.
Metabolic Syndrome
Optimization of high-resolution melting analysis for simultaneous genotyping of two 11?-hydroxysteroid dehydrogenase type 1 gene polymorphisms.
Metabolic Syndrome
Pathophysiology of metabolic syndrome X and its links to the perinatal period.
Metabolic Syndrome
Physiological roles of 11 beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase.
Metabolic Syndrome
Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model.
Metabolic Syndrome
Postnatal programming of glucocorticoid metabolism in rats modulates high-fat diet-induced regulation of visceral adipose tissue glucocorticoid exposure and sensitivity and adiponectin and proinflammatory adipokines gene expression in adulthood.
Metabolic Syndrome
Prenatal programming of metabolic syndrome in the common marmoset is associated with increased expression of 11ss-hydroxysteroid dehydrogenase type 1.
Metabolic Syndrome
Preventing local regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 enhances angiogenesis.
Metabolic Syndrome
Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity?
Metabolic Syndrome
Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss.
Metabolic Syndrome
Relationship of 11?-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase gene polymorphisms with metabolic syndrome and type 2 diabetes.
Metabolic Syndrome
Selection and optimization of MCF-7 cell line for screening selective inhibitors of 11beta-hydroxysteroid dehydrogenase 2.
Metabolic Syndrome
Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome: is the target liver, fat, or both?
Metabolic Syndrome
Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor.
Metabolic Syndrome
Synthesis and biological evaluation of sulfonamidooxazoles and beta-keto sulfones: selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
Metabolic Syndrome
Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes.
Metabolic Syndrome
The role of 11beta-hydroxysteroid dehydrogenase activity in the metabolic syndrome: lessons learned from the animal model.
Metabolic Syndrome
The Role of 11Beta-Hydroxysteroid Dehydrogenase in Metabolic Disease and Therapeutic Potential of 11Beta-HSD1 Inhibitors.
Metabolic Syndrome
The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome.
Metabolic Syndrome
Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.
Metabolic Syndrome
Tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 and pathogenesis of the metabolic syndrome.
Metabolic Syndrome
Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Metabolic Syndrome
Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.
Metabolic Syndrome
Type 1 11beta-hydroxysteroid dehydrogenase as universal drug target in metabolic diseases?
Metabolic Syndrome
Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
Metabolic Syndrome
[Intracellular glucocorticoid reactivating enzyme, 11beta-HSD1 as a promising drug target against metabolic syndrome]
Metabolic Syndrome
[Reduction of obesity-related metabolic risk by modulating tissue exposition to cortisol].
Mineralocorticoid Excess Syndrome, Apparent
Apparent mineralocorticoid excess syndrome in a Brazilian boy caused by the homozygous missense mutation p.R186C in the HSD11B2 gene.
Mineralocorticoid Excess Syndrome, Apparent
Mimicry and well known genetic friends: molecular diagnosis in an Iranian cohort of suspected Bartter syndrome and proposition of an algorithm for clinical differential diagnosis.
Mineralocorticoid Excess Syndrome, Apparent
Serum Cortisol and Cortisone as potential biomarkers of Partial 11?-hydroxysteroid dehydrogenase type-2 Deficiency.
Mineralocorticoid Excess Syndrome, Apparent
[Measurement of free urinary cortisol and cortisone using liquid chromatography associated with tandem mass spectrometry method]
Muscular Atrophy
Lack of contribution of 11betaHSD1 and glucocorticoid action to reduced muscle mass associated with reduced growth hormone action.
Muscular Atrophy
The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
Myotonic Dystrophy
Glucocorticoid metabolism and adrenocortical reactivity to ACTH in myotonic dystrophy.
Myotonic Dystrophy
Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Neoplasm Metastasis
Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.
Neoplasm Metastasis
Type-2 11?-hydroxysteroid dehydrogenase promotes the metastasis of colorectal cancer via the Fgfbp1-AKT pathway.
Neoplasms
11Beta-hydroxysteroid dehydrogenase 1 expression in squamous cell carcinomas of the head and neck.
Neoplasms
11beta-Hydroxysteroid dehydrogenase types 1 and 2 are up- and downregulated in cortisol-secreting adrenal adenomas.
Neoplasms
A variant (rs932335) in the HSD11B1 gene is associated with colorectal cancer in a Chinese population.
Neoplasms
Analysis of alternative promoter usage in expression of HSD11B1 including the development of a transcript-specific quantitative real-time PCR method.
Neoplasms
Augmentation of 11beta-hydroxysteroid dehydrogenase type 1 in LPS-activated J774.1 macrophages--role of 11beta-HSD1 in pro-inflammatory properties in macrophages.
Neoplasms
CTL recognition of a novel HLA-A*0201-binding peptide derived from glioblastoma multiforme tumor cells.
Neoplasms
Cushing's syndrome associated with a nested stromal epithelial tumor of the liver: hormonal, immunohistochemical, and molecular studies.
Neoplasms
Dexamethasone enhances basal and TNF-{alpha}-stimulated production of PAI-1 via the glucocorticoid receptor regardless of 11{beta}-hydroxysteroid dehydrogenase 2 status in human proximal renal tubular cells.
Neoplasms
Effect of pro-inflammatory cytokines on expression and activity of 11beta-hydroxysteroid dehydrogenase type 2 in cultured human term placental trophoblast and human choriocarcinoma JEG-3 cells.
Neoplasms
Effects of a high-salt diet on adipocyte glucocorticoid receptor and 11-beta hydroxysteroid dehydrogenase 1 in salt-sensitive hypertensive rats.
Neoplasms
Expression of 11beta-hydroxysteroid dehydrogenase type 2 in an ACTH-producing small cell lung cancer.
Neoplasms
Expression of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in colorectal cancer.
Neoplasms
Expression of glucocorticoid receptor and 11beta hydroxysteroid dehydrogenase in a case of pulmonary epithelioid haemangioendothelioma.
Neoplasms
Gender-specific links between hepatic 11beta reduction of cortisone and adipokines.
Neoplasms
Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II.
Neoplasms
HSD11B2, RUNX3, and LINE-1 Methylation in Placental DNA of Hypertensive Disorders of Pregnancy Patients.
Neoplasms
Hypothalamic regulation of adiposity: the role of 11beta-hydroxysteroid dehydrogenase type 1.
Neoplasms
Immunohistochemical analysis of 11-beta-hydroxysteroid dehydrogenase type 2 and glucocorticoid receptor in subclinical Cushing's disease due to pituitary macroadenoma.
Neoplasms
Inflammatory mediators down-regulate 11beta-hydroxysteroid dehydrogenase type 2 in a human lung epithelial cell line BEAS-2B and the rat lung.
Neoplasms
Inhibition of 11beta-hydroxysteroid dehydrogenase eliminates impaired glucocorticoid suppression and induces apoptosis in corticotroph tumor cells.
Neoplasms
Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.
Neoplasms
Insulin attenuates the stimulatory effects of tumor necrosis factor alpha on 11beta-hydroxysteroid dehydrogenase 1 in human adipose stromal cells.
Neoplasms
Insulin, CCAAT/enhancer-binding proteins and lactate regulate the human 11?-hydroxysteroid dehydrogenase type 2 gene expression in colon cancer cell lines.
Neoplasms
Luteinizing hormone induces expression of 11beta-hydroxysteroid dehydrogenase type 2 in rat Leydig cells.
Neoplasms
Mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type II expression in renal cell neoplasms: a tissue microarray and quantitative RT-PCR study.
Neoplasms
Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation.
Neoplasms
NAD dependent 11beta-hydroxysteroid dehydrogenase activity in human endometrium and endometrial tumors.
Neoplasms
Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines.
Neoplasms
Role of local 11 beta-hydroxysteroid dehydrogenase type 2 expression in determining the phenotype of adrenal adenomas.
Neoplasms
T cell-mediated inflammation in adipose tissue does not cause insulin resistance in hyperlipidemic mice.
Neoplasms
The inflammatory response seen when human omental adipose tissue explants are incubated in primary culture is not dependent upon albumin and is primarily in the nonfat cells.
Neoplasms
Transcriptional alterations of genes related to fertility decline in male rats induced by chronic sleep restriction.
Neoplasms
Tumor necrosis factor alpha and phorbol 12-myristate-13-acetate down-regulate human 11beta-hydroxysteroid dehydrogenase type 2 through p50/p50 NF-kappaB homodimers and Egr-1.
Neoplasms
Tumor necrosis factor-alpha upregulates 11beta-hydroxysteroid dehydrogenase type 1 expression by CCAAT/enhancer binding protein-beta in HepG2 cells.
Neoplasms
Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
Neoplasms
Type-2 11?-hydroxysteroid dehydrogenase promotes the metastasis of colorectal cancer via the Fgfbp1-AKT pathway.
Neoplasms
Upregulation of 11?-hydroxysteroid dehydrogenase 1 in lymphoid organs during inflammation in the rat.
Neoplasms
[Diseases caused by adrenal dyshormonogenesis. The concept of minor enzymopathy. The 3 beta-hydroxysteroid dehydrogenase block; its possible importance in the pathogenesis of breast cancer]
Nephrosis
Reduced 11beta-hydroxysteroid dehydrogenase activity in experimental nephrotic syndrome.
Nephrotic Syndrome
Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension.
Nephrotic Syndrome
Increased apical targeting of renal ENaC subunits and decreased expression of 11betaHSD2 in HgCl2-induced nephrotic syndrome in rats.
Nephrotic Syndrome
Reduced 11beta-hydroxysteroid dehydrogenase activity in experimental nephrotic syndrome.
Nephrotic Syndrome
Reduced 11beta-hydroxysteroid dehydrogenase activity in patients with the nephrotic syndrome.
Nephrotic Syndrome
Reduced activity of 11beta-hydroxysteroid dehydrogenase type 2 is not responsible for sodium retention in nephrotic rats.
Neurodegenerative Diseases
11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease.
Non-alcoholic Fatty Liver Disease
Association of 11?-hydroxysteroid dehydrogenase type 1 gene polymorphisms with serum alanine aminotransferase activity.
Obesity
11 beta-hydroxysteroid dehydrogenase type 1 promotes differentiation of 3T3-L1 preadipocyte.
Obesity
11-Beta hydroxysteroid dehydrogenase type 2 expression in white adipose tissue is strongly correlated with adiposity.
Obesity
11?-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Obesity
11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization.
Obesity
11beta-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues.
Obesity
11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational approaches.
Obesity
11beta-hydroxysteroid dehydrogenase 2 activity is elevated in severe obesity and negatively associated with insulin sensitivity.
Obesity
11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.
Obesity
11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus.
Obesity
11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory.
Obesity
11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease.
Obesity
11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue and prospective changes in body weight and insulin resistance.
Obesity
11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Obesity
11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.
Obesity
11beta-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation.
Obesity
11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress.
Obesity
11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients.
Obesity
11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.
Obesity
11beta-Hydroxysteroid dehydrogenase Type 1: genetic polymorphisms are associated with Type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle.
Obesity
11{beta}-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response.
Obesity
7-oxysterols modulate glucocorticoid activity in adipocytes through competition for 11beta-hydroxysteroid dehydrogenase type.
Obesity
A combination of polymorphisms in HSD11B1 associates with in vivo 11{beta}-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome.
Obesity
A gene variant of 11?-hydroxysteroid dehydrogenase type 1 is associated with obesity in children.
Obesity
A novel promoter for the 11beta-hydroxysteroid dehydrogenase type 1 gene is active in lung and is C/EBPalpha independent.
Obesity
A novel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis.
Obesity
A Polygenic Model of the Metabolic Syndrome With Reduced Circulating and Intra-Adipose Glucocorticoid Action.
Obesity
Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance.
Obesity
Activation of the hypothalamic-pituitary-adrenal axis in obesity: cause or consequence?
Obesity
Adipose tissue 11{beta}-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome.
Obesity
Adipose tissue expression of 11beta-hydroxysteroid dehydrogenase type 1 in Cushing's syndrome and in obesity.
Obesity
Alteration of 11beta-hydroxysteroid dehydrogenase type 1 in skeletal muscle in a rat model of type 2 diabetes.
Obesity
Association between 11beta-hydroxysteroid dehydrogenase type 1 gene polymorphisms and metabolic syndrome in Bosnian population.
Obesity
Association of HSD11B1 polymorphic variants and adipose tissue gene expression with metabolic syndrome, obesity and type 2 diabetes mellitus: a systematic review.
Obesity
Association studies between microsatellite markers within the gene encoding human 11beta-hydroxysteroid dehydrogenase type 1 and body mass index, waist to hip ratio, and glucocorticoid metabolism.
Obesity
Association study of candidate gene polymorphisms and obesity in a young Mexican-American population from South Texas.
Obesity
Benzothiazole derivatives as novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Obesity
Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver.
Obesity
Cell-type specific regulation of the human 11beta-hydroxysteroid dehydrogenase type 1 promoter.
Obesity
Charting biologically relevant chemical space: a structural classification of natural products (SCONP).
Obesity
Comparison of a homology model and the crystallographic structure of human 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) in a structure-based identification of inhibitors.
Obesity
Conformational flexibility in crystal structures of human 11beta-hydroxysteroid dehydrogenase type I provide insights into glucocorticoid interconversion and enzyme regulation.
Obesity
Cortisol metabolism and visceral obesity: role of 11beta-hydroxysteroid dehydrogenase type I enzyme and reduced co-factor NADPH.
Obesity
Cortisol metabolism in human obesity: impaired cortisone-->cortisol conversion in subjects with central adiposity.
Obesity
Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans.
Obesity
Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue.
Obesity
Depot-specific messenger RNA expression of 11 beta-hydroxysteroid dehydrogenase type 1 and leptin in adipose tissue of children and adults.
Obesity
Depot-specific modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11beta-hydroxysteroid dehydrogenase type 1.
Obesity
Diabetic pregnancy in rats leads to impaired glucose metabolism in offspring involving tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 expression.
Obesity
Differences in associations between HSD11B1 gene expression and metabolic parameters in subjects with and without impaired glucose homeostasis.
Obesity
Different responsiveness in body weight and hepatic 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 1 mrna to 11beta-HSD inhibition by glycyrrhetinic acid treatment in obese and lean zucker rats.
Obesity
Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.
Obesity
Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes.
Obesity
Effects of proportions of dietary macronutrients on glucocorticoid metabolism in diet-induced obesity in rats.
Obesity
Efficacious 11beta-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model.
Obesity
Evidence of altered cortisol metabolism in critically ill patients: a prospective study.
Obesity
Expression of 11beta-hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome.
Obesity
Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity.
Obesity
Expression of the mRNA coding for 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study.
Obesity
Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
Obesity
Functional characterization of the human 11 beta-hydroxysteroid dehydrogenase 1B (11 beta-HSD 1B) variant.
Obesity
Functional effects of polymorphisms in the human gene encoding 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1): a sequence variant at the translation start of 11 beta-HSD1 alters enzyme levels.
Obesity
Gender-dependent association of HSD11B1 single nucleotide polymorphisms with glucose and HDL-C levels.
Obesity
Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome.
Obesity
Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II.
Obesity
Glucocorticoid metabolism and adrenocortical reactivity to ACTH in myotonic dystrophy.
Obesity
Glucocorticoid receptor gene expression in adipose tissue and associated metabolic risk in black and white South African women.
Obesity
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic sindrome.
Obesity
High-throughput screening of 11beta-hydroxysteroid dehydrogenase type 1 in scintillation proximity assay format.
Obesity
Hippocampal 11beta-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression has a diurnal variability that is lost in the obese Zucker rat.
Obesity
Human adipose tissue under in vitro inhibition of 11beta-hydroxysteroid dehydrogenase type 1: differentiation and metabolism changes.
Obesity
Hypothalamic regulation of adiposity: the role of 11beta-hydroxysteroid dehydrogenase type 1.
Obesity
Immortalization of Porcine 11?-Hydroxysteroid Dehydrogenase Type 1-Transgenic Liver Cells Using SV40 Large T Antigen.
Obesity
Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice.
Obesity
INCB-13739, an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for the treatment of type 2 diabetes.
Obesity
Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone.
Obesity
Increased expression of the macrophage markers and of 11beta-HSD-1 in subcutaneous adipose tissue, but not in cultured monocyte-derived macrophages, is associated with liver fat in human obesity.
Obesity
Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone.
Obesity
Influence of short-term dietary weight loss on cortisol secretion and metabolism in obese men.
Obesity
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice.
Obesity
Inhibition of human and rat 11beta-hydroxysteroid dehydrogenase type 1 by 18beta-glycyrrhetinic acid derivatives.
Obesity
Interaction between an 11betaHSD1 gene variant and birth era modifies the risk of hypertension in Pima Indians.
Obesity
Interaction of HSD11B1 and H6PD polymorphisms in subjects with type 2 diabetes are protective factors against obesity: a cross-sectional study.
Obesity
Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats.
Obesity
Lack of association of the 11 beta-hydroxysteroid dehydrogenase type 1 gene 25669dupA polymorphism with obesity and metabolic syndrome.
Obesity
Lack of mutations of type 1 11beta-hydroxysteroid dehydrogenase gene in patients with abdominal obesity.
Obesity
Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice.
Obesity
Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity.
Obesity
Low-dose growth hormone inhibits 11 beta-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity.
Obesity
Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.
Obesity
Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Obesity
Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action.
Obesity
Modification of microsomal 11beta-HSD1 activity by cytosolic compounds: glutathione and hexose phosphoesters.
Obesity
Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice.
Obesity
Obese Zucker rats have reduced mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 1 expression in hippocampus-implications for dysregulation of the hypothalamic-pituitary-adrenal axis in obesity.
Obesity
Omental 11beta-hydroxysteroid dehydrogenase 1 correlates with fat cell size independently of obesity.
Obesity
Optimization of high-resolution melting analysis for simultaneous genotyping of two 11?-hydroxysteroid dehydrogenase type 1 gene polymorphisms.
Obesity
Overexpression of 11beta-Hydroxysteroid Dehydrogenase Type 1 in Hepatic and Visceral Adipose Tissue is Associated with Metabolic Disorders in Morbidly Obese Patients.
Obesity
Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins.
Obesity
Physiological roles of 11 beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase.
Obesity
Preadipocyte 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Is a Keto-Reductase and Contributes to Diet-Induced Visceral Obesity in Vivo.
Obesity
Prenatal programming of metabolic syndrome in the common marmoset is associated with increased expression of 11ss-hydroxysteroid dehydrogenase type 1.
Obesity
Quantitative real-time PCR for the measurement of 11beta-HSD1 and 11beta-HSD2 mRNA levels in tissues of healthy dogs.
Obesity
Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity?
Obesity
Reduced adipose glucocorticoid reactivation and increased hepatic glucocorticoid clearance as an early adaptation to high-fat feeding in Wistar rats.
Obesity
Reduced levels of circulating 7alpha-hydroxy-dehydroepiandrosterone in treated adolescent obese patients.
Obesity
Reduction of hepatic glucocorticoid receptor and hexose-6-phosphate dehydrogenase expression ameliorates diet-induced obesity and insulin resistance in mice.
Obesity
Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss.
Obesity
Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines.
Obesity
Regulatory effect of common promoter polymorphisms on the expression of the 11beta-hydroxysteroid dehydrogenase type 1 gene.
Obesity
Role of 11-beta-hydroxysteroid dehydrogenase type 1 in differentiation of 3T3-L1 cells and in rats with diet-induced obesity.
Obesity
Role of calcitriol and cortisol on human adipocyte proliferation and oxidative and inflammatory stress: a microarray study.
Obesity
Role of glucocorticoids in the physiopathology of excessive fat deposition and insulin resistance.
Obesity
Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity.
Obesity
Steroid hormones related to 11beta-hydroxysteroid dehydrogenase type 1 in treated obesity.
Obesity
Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.
Obesity
Sucrose access differentially modifies 11beta-hydroxysteroid dehydrogenase-1 and hexose-6-phosphate dehydrogenase message in liver and adipose tissue in rats.
Obesity
Suppression of 11{beta}-hydroxysteroid dehydrogenase type 1 with RNA interference substantially attenuates 3T3-L1 adipogenesis.
Obesity
Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes.
Obesity
The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans.
Obesity
The critical role of the N-terminus of 11beta-hydroxysteroid dehydrogenase type 1, as being encoded by exon 1, for enzyme stabilization and activity.
Obesity
The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
Obesity
The glucocorticoid-activating enzyme 11beta-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological considerations.
Obesity
The Role of 11Beta-Hydroxysteroid Dehydrogenase in Metabolic Disease and Therapeutic Potential of 11Beta-HSD1 Inhibitors.
Obesity
Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.
Obesity
Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity.
Obesity
Tissue-specific dysregulation of cortisol regeneration by 11?HSD1 in obesity: has it promised too much?
Obesity
Tissue-specific increases in 11beta-hydroxysteroid dehydrogenase type 1 in normal weight postmenopausal women.
Obesity
Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.
Obesity
Tumor necrosis factor-alpha upregulates 11beta-hydroxysteroid dehydrogenase type 1 expression by CCAAT/enhancer binding protein-beta in HepG2 cells.
Obesity
Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats.
Obesity
Urinary free cortisone, but not cortisol, is associated with urine volume in severe obesity.
Obesity
Vitamin A decreases pre-receptor amplification of glucocorticoids in obesity: study on the effect of vitamin A on 11beta-hydroxysteroid dehydrogenase type 1 activity in liver and visceral fat of WNIN/Ob obese rats.
Obesity
Weight Loss after Gastric Bypass Surgery in Women Is Followed by a Metabolically Favorable Decrease in 11{beta}-Hydroxysteroid Dehydrogenase 1 Expression in Subcutaneous Adipose Tissue.
Obesity
Weight loss increases 11beta-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue.
Obesity
[Reduction of obesity-related metabolic risk by modulating tissue exposition to cortisol].
Obesity, Abdominal
11Beta-hydroxysteroid dehydrogenase type 1 in differentiating omental human preadipocytes: from de-activation to generation of cortisol.
Obesity, Abdominal
11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes.
Obesity, Abdominal
11beta-Hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds.
Obesity, Abdominal
Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity.
Obesity, Abdominal
Association studies between microsatellite markers within the gene encoding human 11beta-hydroxysteroid dehydrogenase type 1 and body mass index, waist to hip ratio, and glucocorticoid metabolism.
Obesity, Abdominal
Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver.
Obesity, Abdominal
Circulating 11beta-hydroxysteroid dehydrogenase type 1 mRNA and cardiovascular risk factors.
Obesity, Abdominal
Cortisol metabolism and visceral obesity: role of 11beta-hydroxysteroid dehydrogenase type I enzyme and reduced co-factor NADPH.
Obesity, Abdominal
Cortisol metabolism in human obesity: impaired cortisone-->cortisol conversion in subjects with central adiposity.
Obesity, Abdominal
Cortisol, 11 beta-hydroxysteroid dehydrogenase type 1 and central obesity.
Obesity, Abdominal
Depot-specific modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11beta-hydroxysteroid dehydrogenase type 1.
Obesity, Abdominal
Differentiation of adipose stromal cells: the roles of glucocorticoids and 11beta-hydroxysteroid dehydrogenase.
Obesity, Abdominal
Down-regulation of adipose 11beta-hydroxysteroid dehydrogenase type 1 by high-fat feeding in mice: a potential adaptive mechanism counteracting metabolic disease.
Obesity, Abdominal
Enzymology and molecular biology of glucocorticoid metabolism in humans.
Obesity, Abdominal
Expression of genes related to glucocorticoid action in human subcutaneous and omental adipose tissue.
Obesity, Abdominal
Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension.
Obesity, Abdominal
Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle.
Obesity, Abdominal
H6PDH interacts directly with 11beta-HSD1: implications for determining the directionality of glucocorticoid catalysis.
Obesity, Abdominal
Human adipose tissue under in vitro inhibition of 11beta-hydroxysteroid dehydrogenase type 1: differentiation and metabolism changes.
Obesity, Abdominal
Insulin and dexamethasone dynamically regulate adipocyte 11beta-hydroxysteroid dehydrogenase type 1.
Obesity, Abdominal
Lack of mutations of type 1 11beta-hydroxysteroid dehydrogenase gene in patients with abdominal obesity.
Obesity, Abdominal
Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Obesity, Abdominal
Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins.
Obesity, Abdominal
Pathophysiology of metabolic syndrome X and its links to the perinatal period.
Obesity, Abdominal
Quantitative measurements of corticosteroids in ex vivo samples using on-line SPE-LC/MS/MS.
Obesity, Abdominal
Reduced 11beta-hydroxysteroid dehydrogenase type 1 activity in obese boys.
Obesity, Abdominal
Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss.
Obesity, Abdominal
Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines.
Obesity, Abdominal
Testosterone Stimulates Adipose Tissue 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Expression in a Depot-Specific Manner in Children.
Obesity, Abdominal
The functional consequences of 11beta-hydroxysteroid dehydrogenase expression in adipose tissue.
Obesity, Abdominal
Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity.
Obesity, Abdominal
Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action.
Obesity, Abdominal
Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Obesity, Abdominal
Tissue-specific increases in 11beta-hydroxysteroid dehydrogenase type 1 in normal weight postmenopausal women.
Obesity, Abdominal
Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.
Obesity, Abdominal
[Correlations between the hypothalamo-pituitary-adrenal axis and the metabolic syndrome]
Obesity, Abdominal
[Glucocorticoids, 11 beta-hydroxysteroid dehydrogenase type 1, and visceral obesity]
Obesity, Morbid
11beta-hydroxysteroid dehydrogenase 2 activity is elevated in severe obesity and negatively associated with insulin sensitivity.
Obesity, Morbid
Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
Obstetric Labor, Premature
Effect of pro-inflammatory cytokines on expression and activity of 11beta-hydroxysteroid dehydrogenase type 2 in cultured human term placental trophoblast and human choriocarcinoma JEG-3 cells.
Obstetric Labor, Premature
Role of fetal membranes in signaling of fetal maturation and parturition.
Ocular Hypertension
In vivo evaluation of 11beta-hydroxysteroid dehydrogenase activity in the rabbit eye.
Ocular Hypertension
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension.
Oropharyngeal Neoplasms
11Beta-hydroxysteroid dehydrogenase 1 expression in squamous cell carcinomas of the head and neck.
Osteoarthritis
Differential expression, function and response to inflammatory stimuli of 11beta-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation.
Osteolysis
11beta-hydroxysteroid dehydrogenase type 1 expression in periprosthetic osteolysis.
Osteonecrosis
[Genetic expression differences of 11 beta-hydroxysteroid dehydrogenase in the bone microvascular endothelial cells derived from different regions of the human femoral head].
Osteoporosis
11beta-hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone.
Osteoporosis
11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Osteoporosis
11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.
Osteoporosis
11beta-Hydroxysteroid dehydrogenase: a regulator of glucocorticoid response in osteoporosis.
Osteoporosis
11{beta}-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response.
Osteoporosis
Characterization of 11beta-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines.
Osteoporosis
Circulating cortisone levels are associated with biochemical markers of bone formation and lumbar spine BMD: the Hertfordshire Cohort Study.
Osteoporosis
Expression and functional consequences of 11beta-hydroxysteroid dehydrogenase activity in human bone.
Osteoporosis
HSD11B1 polymorphisms predicted bone mineral density and fracture risk in postmenopausal women without a clinically apparent hypercortisolemia.
Osteosarcoma
Characterization of 11beta-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines.
Osteosarcoma
Expression and functional consequences of 11beta-hydroxysteroid dehydrogenase activity in human bone.
Osteosarcoma
Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation.
Osteosarcoma
Prereceptor regulation of glucocorticoid action by 11beta-hydroxysteroid dehydrogenase: a novel determinant of cell proliferation.
Osteosarcoma
Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone loss.
Ovarian Cysts
Implication of cortisol and 11beta-hydroxysteroid dehydrogenase enzymes in the development of porcine (Sus scrofa domestica) ovarian follicles and cysts.
Ovarian Cysts
Inactivation of glucocorticoids by 11beta-hydroxysteroid dehydrogenase enzymes increases during the meiotic maturation of porcine oocytes.
Ovarian Cysts
Ovarian modulators of 11beta-hydroxysteroid dehydrogenase (11beta HSD) activity in follicular fluid from bovine and porcine large antral follicles and spontaneous ovarian cysts.
Ovarian Diseases
Experimental micropolycystic ovarian disease. I. Measurement of body weight, ovarian weight and histochemical activity of 17 beta-hydroxysteroid dehydrogenase.
Overweight
Depot-specific messenger RNA expression of 11 beta-hydroxysteroid dehydrogenase type 1 and leptin in adipose tissue of children and adults.
Overweight
Endurance exercise training increases adipose tissue glucocorticoid exposure: adaptations that facilitate lipolysis.
Overweight
Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity.
Pituitary ACTH Hypersecretion
Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion.
Pituitary ACTH Hypersecretion
Immunohistochemical analysis of 11-beta-hydroxysteroid dehydrogenase type 2 and glucocorticoid receptor in subclinical Cushing's disease due to pituitary macroadenoma.
Pituitary ACTH Hypersecretion
Inhibition of 11beta-hydroxysteroid dehydrogenase eliminates impaired glucocorticoid suppression and induces apoptosis in corticotroph tumor cells.
Pituitary ACTH Hypersecretion
Modulatory effect of BclI GR gene polymorphisms on the obesity phenotype in Brazilian patients with Cushing's disease.
Pituitary Neoplasms
Hormonal Regulation of Glucocorticoid Inactivation and Reactivation in ?T3-1 and L?T2 Gonadotroph Cells.
Pneumonia
Inflammatory mediators down-regulate 11beta-hydroxysteroid dehydrogenase type 2 in a human lung epithelial cell line BEAS-2B and the rat lung.
Polycystic Ovary Syndrome
11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Polycystic Ovary Syndrome
A combination of polymorphisms in HSD11B1 associates with in vivo 11{beta}-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome.
Polycystic Ovary Syndrome
A study of the hexose-6-phosphate dehydrogenase gene R453Q and 11beta-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome.
Polycystic Ovary Syndrome
Association Analysis between the Polymorphisms of HSD11B1 and H6PD and Risk of Polycystic Ovary Syndrome in Chinese Population.
Polycystic Ovary Syndrome
Association Study of CYP17 and HSD11B1 in Polycystic Ovary Syndrome Utilizing Comprehensive Gene Coverage.
Polycystic Ovary Syndrome
Endogenous inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 do not explain abnormal cortisol metabolism in polycystic ovary syndrome.
Polycystic Ovary Syndrome
Expression of 11beta-hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome.
Polycystic Ovary Syndrome
Genetic variants of the HSD11B1 gene promoter may be protective against polycystic ovary syndrome.
Polycystic Ovary Syndrome
Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase.
Polycystic Ovary Syndrome
Increased 5alpha-reductase and normal 11beta-hydroxysteroid dehydrogenase metabolism of C19 and C21 steroids in a young population with polycystic ovarian syndrome.
Polyuria
Phenotypic analysis of mice bearing targeted deletions of 11beta-hydroxysteroid dehydrogenases 1 and 2 genes.
Pre-Eclampsia
11beta-Hydroxysteroid dehydrogenase activity in pregnancies complicated by hydatidiform mole.
Pre-Eclampsia
Alteration in methylation level at 11?-hydroxysteroid dehydrogenase type 2 gene promoter in infants born to preeclamptic women.
Pre-Eclampsia
Angiotensin II regulates 11beta-hydroxysteroid dehydrogenase type 2 via AT2 receptors.
Pre-Eclampsia
Decreased gene expression of 11beta-hydroxysteroid dehydrogenase type 2 and 15-hydroxyprostaglandin dehydrogenase in human placenta of patients with preeclampsia.
Pre-Eclampsia
Ontogeny of placental structural development and expression of the renin-angiotensin system and 11beta-HSD2 genes in the rabbit.
Pre-Eclampsia
The transplacental passage of prednisolone in pregnancies complicated by early-onset HELLP syndrome.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Differential regulation of 11beta-hydroxysteroid dehydrogenase-1 by dexamethasone in glucocorticoid-sensitive and -resistant childhood lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of 11beta-hydroxysteroid dehydrogenase 2 contributes to glucocorticoid resistance in lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Reciprocal Regulation of HSD11B1 and HSD11B2 Predicts Glucocorticoid Sensitivity in Childhood Acute Lymphoblastic Leukemia.
Pregnancy Complications
Maternal depressive symptoms during pregnancy, placental expression of genes regulating glucocorticoid and serotonin function and infant regulatory behaviors.
Pregnancy Complications
Ontogeny of placental structural development and expression of the renin-angiotensin system and 11beta-HSD2 genes in the rabbit.
Premature Birth
[Influence of dexamethasone on expression of 11beta-HSD2 in primary cultured cytotrophoblasts from human preterm placenta]
Prostatic Neoplasms
Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines.
Prostatic Neoplasms
Modulation of 11beta-hydroxysteroid dehydrogenase expression by bombesin: a possible mechanism for glucocorticoid resistance in androgen independent prostate cancer.
Prostatic Neoplasms
Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Proteinuria
Expression of renal 11beta-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function.
Proteinuria
Reduced 11beta-hydroxysteroid dehydrogenase activity in experimental nephrotic syndrome.
Rheumatic Heart Disease
[Atrial 11beta-hydroxysteroid dehydrogenase type 2 expression in rheumatic heart disease patients with or without atrial fibrillation]
Rosacea
TLR3 augments glucocorticoid-synthetic enzymes expression in epidermal keratinocytes; Implications of glucocorticoid metabolism in rosacea epidermis.
Sarcopenia
Increased skeletal muscle 11?HSD1 mRNA is associated with lower muscle strength in ageing.
Sleep Deprivation
Sleep duration and fragmentation in relation to leukocyte DNA methylation in adolescents.
Sleep Deprivation
Transcriptional alterations of genes related to fertility decline in male rats induced by chronic sleep restriction.
Small Cell Lung Carcinoma
Expression of 11beta-hydroxysteroid dehydrogenase type 2 in an ACTH-producing small cell lung cancer.
steroid 21-monooxygenase deficiency
A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia.
Synovitis
11 Beta-hydroxysteroid dehydrogenase type 1 regulates synovitis, joint destruction, and systemic bone loss in chronic polyarthritis.
unspecific monooxygenase deficiency
Evidence for a role of sterol 27-hydroxylase in glucocorticoid metabolism in vivo.
Virus Diseases
Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines.
Vitamin D Deficiency
Maternal vitamin D deficiency during rat gestation elicits a milder phenotype compared to the mouse model: Implications for the placental glucocorticoid barrier.
Xanthomatosis, Cerebrotendinous
Evidence for a role of sterol 27-hydroxylase in glucocorticoid metabolism in vivo.
Xanthomatosis, Cerebrotendinous
Studies of the mechanism of the increased biosynthesis of cholestanol in cerebrotendinous xanthomatosis. The activity of delta 5-3 beta-hydroxysteroid dehydrogenase.
html completed